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ABSTRACT
Most human genes undergo alternative splicing, and many abnormal splicing processes
are associated with human diseases. However, the molecular relationship between
alternative splicing and tumorigenesis is not well understood. Here, we identified novel
Krüppel-like factor 4 (KLF4) splicing variants produced by exon skipping in human
cancer cell lines as well as colon tumor tissues. To elucidate the mechanism involved in
KLF4 alternative splicing, we developed KLF4 minigene system and found that RNA
binding motif protein 5 (RBM5) plays an important role in KLF4 splicing, as assessed by
gain and loss of functional studies. Several anti-tumorigenic compounds were also tested
for KLF4 splicing. Interestingly, sulindac sulfide restored wild type KLF4 (KLF4L)
expression and this is mediated by dephosphorylation of RBM5. Another splicing variant,
small KLF4 (KLF4S), localizes in the cytoplasm and nucleus, and antagonizes
transcriptional activity of wild type KLF4. Our data suggest that RBM5 plays a pivotal
role in the alternative splicing of KLF4, and these splicing variant forms may impact
tumorigenesis.
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CHAPTER 1
Introduction:
Alternative splicing and colorectal cancer
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1.1. Colorectal cancer
Colorectal cancer is the third most common cancer and leading cause of cancer death in
the United States; approximately 5-7% of individuals developing colorectal cancer.
Based on the National Cancer Institute Surveillance Epidemiology and End Results
(SEER) Stat Fact Sheet, it is estimated that 142,570 people (72,090 men and 70,480
women) will be diagnosed with and 51,370 people will die of colorectal cancer in 2010.
The risk of colorectal cancer starts to increase before age 50 and significantly boosts in
the 60s and 70s (Chan and Giovannucci 2010). Around 70% of colorectal cancers are
found in the first six feet of the colon and the other 30% occur in the last 10 inches of the
rectum (Figure 1-1). It is evident that further studies with molecular-based approach are
required to reduce incidence and risk of colorectal cancer.

Figure 1-1. Colon cancer and polyp. The human colon has four sections, including
ascending, transverse, descending, and sigmoid colon. Benign polyps develop when
DNA damage occurs in the inner lining of the colon cell (Right). Over the years,
polyps in the colon are able to become colon cancer (Left).
Medicine Net. Inc.
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Illustration from

1.2. Hereditary colorectal cancer
There are many risk factors for colorectal cancer, such as genetic background, age, diet,
and carcinogen exposure. About 67-95% of colorectal cancers are sporadic and the other
5-33% are hereditary (Burt and Neklason 2005, Grady 2003) (Figure 1-2).
In case of genetic factor, hereditary colorectal cancer can be classified into four groups
depending on types and patterns of adenomas (Abdel-Rahman and Peltomaki 2004). The
first group is more than thousands of adenomas polyps are able to become malignant
including familial adenomatous polyposis (FAP) and Turcot’s syndrome. The second
group is less than 1000 adenomatous polyps within the colon such as MYH-associated
polyposis. The third group is a few adenomas with the capacity to turn malignant
including hereditary nonpolyposis colorectal cancer syndrome (HNPCC), also known as
Lynch syndrome. Final group is syndromes with hamartomatous polyps which contain a
mixture of normal and inflammatory polyps, such as Peutz-Jeghers syndrome, familial
juvenile polyposis and Cowden syndrome (Schreibman et al 2005). However, FAP and
HNPCC is the most common hereditary colorectal cancer (Figure 1-2).

Figure 1-2. Colon cancer and inheritance. Around 33% cases of colorectal cancer is
hereditary and rest of cases are sporadic (Figure from Burt and Neklason 2005).

3

FAP is an autosomal dominant syndrome in which over a thousand polyps develop in the
patient’s colon. FAP is caused by mutation of adenomatous polyposis (APC) gene, which
is a tumor-suppressor gene (Burt and Neklason 2005). Mutation of APC causes
constitutive activation of Wnt-signaling pathway, resulting in uncontrolled cell growth
(Goss and Groden 2000). Approximately 95% of APC mutations produce truncated APC
protein by frameshift or nonsense mutation (Sieber et al 2000). Because these truncations
cause loss of the domains required for binding to β-catenin and to microtubules. The
interaction of APC with β-catenin and microtubules is essential for its tumor suppressor
activity (Aoki and Taketo 2007).
HNPCC is also an autosomal dominant syndrome which has colon cancer as well as
endometrium, ovary, stomach, small intestine, gastric, urinary tract, renal cell,
gallbladder, skin, and brain (Lynch et al 1993). HNPCC is associated with mutations of
mutation mismatch repair (MMR) gene including MutL homolog 1 (MLH1), MutS
homolog 2 (MSH2), and MutS homolog 6 (MSH6) (Burt and Neklason 2005). MMR
system, which is DNA mismatch repair system, consists of a complex of proteins that
recognize and repair the mismatched base-pairs during DNA replication. In addition,
Some HNPCC patients have microsatellite instability (MSI), which is mutation by defect
of MMR system in repeated DNA sequence within a chromosome. MSI cancer cells
show 100 times more mutation rate than microsatellite stable cancer cells (Lynch 1999).
Therefore, mutation in the MMR gene showed severe phenotypes by accumulations of
mismatch repairs. Although there has been many studies involving hereditary colorectal
cancer, sporadic colorectal cancer accounts for around 70% of colorectal cancers.
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Therefore, the detailed molecular mechanism of sporadic colorectal cancer needs to be
investigated.

1.3. Genetic markers in colorectal cancer
Colon cancer progression involves the accumulation of sequential events that either
activate oncogenes or inhibit the action of tumor suppressor genes, resulting in the
transformation of normal colonic epithelial cells into adenocarcinoma which takes
between 10 to 15 years (Figure 1-3). The most commonly affected genes in this process
including APC, KRAS, BRAF, SMAD4, BAX, CDC4, and p53 (Grady 2005, Walther et
al 2009).
Many reports have suggested that mutations in APC gene are responsible for colorectal
cancer. Generally, APC plays an important role in the regulation of cytoplasmic β-catenin
by formation of multi-protein complex with Casein Kinase 1α (CK1α), Axin, and
glycogen synthase kinase-3β (GSK-3β). Once β-catenin is bound to this complex, it is
phosphorylated by CK1α and GSK-3β, which promotes its ubiquitin-mediated
proteasomal degradation (Aoki and Taketo 2007, Fearon 1995).
On the other hand, Wnt signaling pathway involves the stabilization and nuclear
translocation of β-catenin. Once Wnt ligand binds and activates their membrane receptor,
Frizzled, cytoplasmic Dishevelled (Dvl) induces phosphorylation of Axin and
degradation of down steam targets. As a result of the degradation, β-catenin
phosphorylation is prevented and is free to translocate into the cell nucleus. Nuclear βcatenin is a co-activator of the T-Cell Factor (TCF)/Lymphoid Enhancer Factor (LEF)
family of transcription factors that induce the transcription of several target genes that
5

control tumorigenesis including cyclin D1, CD44, PPARδ, and c-MYC (He et al 1998,
Tetsu and McCormick 1999, Wielenga et al 1999).

Figure 1-3. Chromosomal instability model of colorectal cancer. The initial step in
tumorigenesis is associated with loss of adenomatous polyposis (APC) to form early
adenoma. Mutations in KRAS, which is a small GTPase, are allowed to form
intermediate adenoma. Next, late adenoma acquires loss of SMAD4, which is
downstream of transforming growth factor-β (TGF-β) in chromosome 18q. Finally,
mutations in p53 result in carcinoma. In addition, microsatellite instability
including Wnt signaling pathway, BRAF, CDC4, and BAX is linked to each step of
cancer progression (modified from Walther et al., 2009).
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It has been reported that mutation of RAS in human cancer is common and around 20%
of all human cancer has a mutation in one of the RAS genes. RAS is a protein that plays
an important role in controlling the activity of several signaling pathways that are
responsible for the regulation of cell proliferation. The presence of mutant RAS is
responsible for the deregulation of cellular processes such as programmed cell death,
angiogenesis, and tumor invasion. Three different members of the RAS family are found
to be mutated in human cancer, including H-RAS, K-RAS and N-RAS (Downward 2003).
Especially K-RAS is important in colorectal tumorigenesis. The target of RAS is RAF, a
serine/threonine kinase. Once phosphorylated, RAF activates mitogen-activated protein
kinase (MAPK) cascades, including MEK1/2 and Erk1/2. The activation of Erk induces
its translocation to the cell nucleus, where it promotes the formation of the AP-1
transcription factor (FOS/JUN) that regulates the expression of proteins such as cyclin D1.
Several reports have established that the particular effects of the RAS signaling pathway
are strongly influenced by the cellular context. For example, the presence of activated
RAS in immortalized cells promotes tumorigenesis, whereas in primary cells, activated
RAS can induce cell cycle arrest (Mulder 2000).
Many studies show that TGF-β has the ability to regulate both cell proliferation and
apoptosis at different stages of colon cancer development. SMAD is downstream of this
pathway and also involved in transition stage from intermediate adenoma to late adenoma
in coloreactal tumorigenesis (Derynck and Zhang 2003, Fearon and Vogelstein 1990).
Especially, SMAD4 is an important tumor suppressor gene is located in chromosome
18q21, a region with frequent genetic losses in colorectal cancer (Alazzouzi et al 2005).
The receptor-phosphorylated SMAD2 and SMAD3 demonstrate high affinity for SMAD4
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binding. Once the complex SMAD2/3 and SMAD4 is formed, the complex translocates
into the nucleus where it regulates the transcription of genes regulated by TGF-β.

1.4 KLF4 expression in cancer
So far, at least 25 members of Krüppel-like factor (KLF) family have been reported in
human including SP1-like and KLF-like factors (Dang et al 2000b, Kaczynski et al 2003,
Suske et al 2005, Turner and Crossley 1999). Particularly, KLF4 is strongly associated
with tumorigenesis and regulation of proliferation of GI tract epithelium (Wei et al 2006).
KLF4 is a member of the C2H2-type zinc finger protein family, also known as gutenriched KLF (GKLF) or epithelial zinc finger (EZF) (Garrett-Sinha et al 1996). KLF4
binds to GC-rich elements, which is a conserved DNA binding sequence CACCC in the
promoter region (Sogawa et al 1993). KLF4 acts as a transcription regulator to diverse
target genes involved in cell differentiation, proliferation, and apoptosis (Katz et al 2002,
Rowland and Peeper 2006, Wei et al 2006, Yoon et al 2003) (Table 1).
KLF4 protein is highly expressed in epithelial tissues, including the skin, lung, and
intestine. In addition, KLF4 is detected in the differentiated terminal epithelial cells in the
villus border of the small intestine and the upper crypt region of the large intestine (TonThat et al 1997). Significant reduction of KLF4 mRNA levels was detected in colorectal
adenoma and adenocarcinoma, compared with normal tissues, suggesting relevance of
KLF4 in colorectal tumorigenesis (Dang et al 2000a, Wei et al 2005).
In vivo study using KLF4 knockout mice showed that KLF4 is essential for the barrier
function of skin and for terminal differentiation of goblet cells in the colon of newborn
mice (Katz et al 2002, Segre et al 1999). Moreover, it has been shown that KLF4
8

interacts with β-catenin and inhibits β-catenin signaling, suggesting that cross talk
between KLF4 and β-catenin plays an important role in colorectal tumorigenesis (Zhang
et al 2006).
It has been shown that KLF4 has dual functions such as tumor suppressor and oncogenic
activity in tumorigenesis (Rowland and Peeper 2006, Wei et al 2006). In tumor
suppressor aspect of KLF4, deletion mutation and methylation on the KLF4 gene locus
were found in coloreactal and gastric cancers (Wei et al 2005, Zhao et al 2004). In
addition, gastric tissue specific KLF4 knockout mice showed development of hyperplasia
and polyps in stomach compared with wild type (Katz et al 2005). Investigation of human
gastric cancer patients revealed that loss of KLF4 takes places at early stages in the
progression of cancer (Wei et al 2005).
In contrast, ectopic overexpression of KLF4 in basal keratinocytes using inducible
transgenic mice showed that squamous hyperplasia and dysplasia, indicating the
oncogenic effect of KLF4 (Foster et al 2005), and overexpression of KLF4 was found
around 70% of primary human breast cancers (Foster et al 2000). KLF4 has been shown
as a downstream of p53 such that KLF4 is required for p53-mediated induction of cyclindependent kinase inhibitor 1A (CDKN1A or p21CIP/WAF) in response to DNA damage
resulting cell cycle arrest (Zhang et al 2000). Even though many clinical evidences and
genetic and cell biology studies have shown a strong association between KLF4 and
tumorigenesis, the regulation of KLF4 itself including transcription, post-transcription,
and translation is not investigated in detail to provide a definitive role of KLF4 during
tumorigenesis.
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Table 1. KLF4 regulated genes (modified from Wei et al., 2006).
Gene name

Gene function

Expression level

Cyclin D1

Cell cycle

Down regulation

Orinithine decarboxylase

Cell proliferation

Down regulation

SM α-actin

Cell differentiation

Down regulation

Laminin1

Tissue homeostasis

Down regulation

Histone decarboxylase

Enzyme

Down regulation

CD11d

Cell adhesion

Down regulation

CYP1A1

Drug-metabolizing enzyme

Down regulation

p21 (WAF1/Cip1)

Cyclin-dependent kinase inhibitor

Down regulation

Keratin 4

Cell differentiation

Up regulation

Keratin 19

Stem cell marker

Up regulation

Laminin α 3A

Cell differentiation

Up regulation

Laminin γ-1 chain

Cell differentiation

Up regulation

Intestinal alkaline phosphatase

Cell differentiation

Up regulation

Small praline-rich protein 1A

Cell differentiation

Up regulation

Cytokeratin 4

Cell differentiation

Up regulation

p27KIP1

Cell cycle

Up regulation

p53

Cell cycle, DNA damage

Up regulation

A33antigen

Intestinal epithelial cell marker

Up regulation

Urokinase-type plasminogen Proteolysis
activator receptor

Up regulation
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1.5 NSAIDs in colorectal cancer
Nonsteroidal ant-inflammatory drugs (NSAIDs), including aspirin, indomethacin,
piroxicam, ibuprofen, and sulindac, are used to treat pain, fever, and inflammation
(Ulrich et al 2006). NSAIDs inhibit the activity of cycloxygenase-2 (COX-2) enzymes
that plays a key role in the prostaglandin biosynthesis (Vane 1971). Arachidonic acid
(AA),

the

common

precursor

of

eicosanoids,

is

stored

at

the

membrane

glycerophospholipids and released by the hydrolytic action of phospholipase A2 (PLA2)
enzymes. Next, AA is metabolized to the unstable intermediate prostanoid, PGH2, by the
action of COX enzymes (COX-1 and COX-2). It is generally considered that COX-1 is
constitutively expressed in a variety of cells and plays a housekeeping role. However,
COX-2 is a stimulus-inducible enzyme that is associated with inflammation, pain, fever
and cancer. In table 2, COX-1 or COX-2 specific NSAIDs are listed (Ulrich et al 2006).
In addition to their anti-inflammatory activity, NSAIDs are effective chemopreventive
agents against colorectal cancer (Chan et al 2005, Thun et al 1991). However, long term
treatment of aspirin and other NSAIDs can result in gastrointestinal ulceration and
bleeding. This gastric problem is due to chronic inhibition of prostaglandin production
via COX-1 inhibition in the gastric mucosa (Williams et al 1999). COX-2 selective
inhibitors do not exhibit these side effects (Masferrer et al 1994); however, recent studies
suggest that COX-2 selective inhibitors exhibit cardiovascular toxicity (McGettigan and
Henry 2006, Solomon et al 2005).
It has been shown that sulindac treatment to FAP patients showed complete regression of
colorectal adenomatous polyps in some cases, and partial regression (Luk 1996).
Sulindac is a pro-drug metabolized by the liver and the colonic bacteria by irreversible
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oxidation to sulindac sulfone and reversible reduction to sulindac sulfide (Figure 1-4).
The animal studies with sulindac derivatives showed approximately twice as potent as
sulindac in suppressing tissue inflammation (Hare et al 1977, Shen and Winter 1977). In
addition, sulindac sulfide is at least 5,000 fold more potent than sulindac sulfone at
inhibiting prostaglandin synthesis (Piazza et al 1997). However, molecular mechanism of
sulindac sulfide to prevent colorectal tumorigenesis has not been elucidated in details.

Figure 1-4. Sulindac sulfide is a metabolite from sulindac by colonic bacteria
(Marnett 1992).
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Table 2. NSAIDs and COX inhibition (modified from Ulrich et al., 2006).
Family/class

Drug

Arylacetic acid

Naproxen

COX1 and COX2

Rheumatic diseases, inflammation, pain

Phenylalkanoic acid

Flurbiprofen

COX1 selective

Rheumatic diseases

Benzeneacetic acid

Diclofenac

COX2 selective

Rheumatic diseases, pain

Indene

Sulindac

COX1 and COX2

Rheumatic diseases, inflammation

Indomethacin

COX1 and COX2

Rheumatic diseases. Inflammation

Oxaprozin

COX1 and COX2

Rheumatic diseases

Ibuprofen

COX1 and COX2

Rheumatic diseases, pain, fever

Ketoprofen

COX1 selective

Rheumatic diseases, pain

Aspirin

COX1 and COX2

Rheumatic and heart diseases, pain, inflammation

Disalcid

COX1 selective

Rheumatic diseases, pain

Pyranocarbonic acid

Etodolac

COX2 selective

Rheumatic diseases, pain

Pyrroleacetic acid

Tolmetin

COX1 and COX2

Rheumatic diseases

Oxicam

Piroxicam

COX1 and COX2

Rheumatic diseases

Meloxicam

COX2 selective

Rheumatic diseases

Lornoxicam

COX1 and COX2

Rheumatic diseases, pain

Naphthyalkanone

Nabumetone

COX1 and COX2

Rheumatic diseases

Pyrazole

Valdecoxib

COX2 selective

Rheumatic diseases, pain

Celecoxib

COX2 selective

Rheumatic diseases, pain

Rofecoxib

COX2 selective

Rheumatic diseases, pain

Propionic acid

Salicylate

Furanone

COX or COX2
inhibitor
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Approved indications

1.6 mRNA splicing
Most of eukaryote genes contain multiple exons and introns. In order to eliminate noncoding regions of precursor mRNAs (pre-mRNAs), conserved RNA sequences are
marked in boundaries between exons and introns. 5’ splice site (donor) and 3’ splice site
(acceptor) refer to as the GU-AG role. The branch point sequence (BPS) is necessary to
mRNA splicing process as well (Figure 1-5). The splicing reaction is mediated by the
spliceosome, and consists of five small nuclear RNA and core protein with hundreds of
associated proteins (Black 2003). Most of splicing processes obey the GU-AG rule;
however, some minor case reported the AU-AC rule in exon-intron recognition sites
(Tarn and Steitz 1996). Depending upon nucleotides variation from the consensus
sequences on the 5’ or 3’ splice site, the binding affinity of the spliceosome could be
changed.

Figure 1-5. Consensus sequences for the mRNA splicing. The 5’ splice site (donor)
begins with a GU dinucleotide and a 3’ splice site (acceptor) ends with AG
dinucleotide, indicated by red letters. The branch point sequence (branch site) is
located within the middle of intron. The letter “y” indicates pyrimidine and n is any
nucleotide (modified from Srebrow and Kornblihtt 2006).
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1.7 Biochemical reaction of mRNA splicing
There is two-step biochemical reaction in mRNA splicing via spliceosome and selfsplicing transesterification (Figure 1-6). Initial biochemical step is the 2’-hydroxyl group
of the branch point adenosine within intron starts nucleophilic attack at the 5’ splice site
and then, intron makes a lariat intermediate form. In the second biochemical reaction, 3’hydroxyl group on the cleaved 5’ splice site attacks to the phosphate at the 3’ splice site
and then, the two exons are ligated to each other and the intron lariat are released (Black
2003, Fedor 2008).

Figure 1-6. Biochemical reaction of mRNA splicing. The first step produces a intron
lariat by nucleophilic attack from 2’-hydroxyl adenosine to the 5’ splice site (donor).
The second step produces a free intron lariat and joined two exons by the
nucleophilic attack from donor to acceptor (3’ splice site). Figure is modified from
Fedor 2008.
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1.8 Dynamic assembly of the spliceosome
The spliceosome is a major protein complex for the pre-mRNA splicing reaction which is
consists of five uridine-rich small ribonucleoprotein (snRNP) complexes and over 200
accessory proteins (Black 2003, Jurica and Moore 2003). U1, U2, U4, U5, and U6 snRNP
interact with the conserved exon-intron boundaries to catalyze intron excision and exon
ligation (House and Lynch 2008).
A series of spliceosome components dynamically assemble to make up several
intermediate complexes including the E, A, B, and C complex. For the first step, the U1
snRNP binds to the 5’ splice site and the U2 auxiliary factor heterodimer (U2AF65/35)
binds to the polypyrimidine tract and the 3’ splice site. The U1 and U2AF bound at the
end of intron becomes the early (E) complex or commitment complex by ATPindependent formation (Reed 1996). The E complex recruits the U2 snRNP, which binds
to the branch point, to form the A complex. Additional binding of tri-snRNP including
U4, U5, and U6 becomes the B complex by SR proteins which facilitate the formation of
the B complex in an ATP-dependent manner (Roscigno and Garcia-Blanco 1995). Finally,
the catalytic (C) complex is formed by the extensive rearrangement of snRNPs. For
example, the U1 snRNP is replaced with the U6 snRNP to interact with the 5’ splice site
and the U1 and U4 snRNP is released from the spliceosome complex (Figure 1-7). The C
complex catalyzes the two step biochemical reaction of mRNA splicing (Figure 1-6) as a
result; exons are joined and exported to the cytoplasm for the next translation. The
spliced lariat introns are degraded by several enzymes and many spliceosome
components are recycled (Cheng et al 2006, Martin et al 2002).
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Figure 1-7. Dynamic assembly of spliceosome. For the E complex the U1 snRNP
binds to the 5’ splice site and U2AF binds to the polypyrimidine tract and 3’ splice
site. Next, the U2 snRNP binds to the branch point to form the A complex.
Subsequently, the U4, U5, and U6 snRNP is recruited to the spliceosome machinery
for the B complex. Finally, dynamic rearrangement takes place in the C complex;
U6 snRNP replaces U1 snRNP at the 5’ splice site. The U1 and U4 snRNP is released
from the C complex (modified from House and Lynch 2008).
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1.9 Alternative splicing patterns
Alternative splicing is a major post-transcription regulation mechanism to generate
multiple gene products from single primary transcript in higher eukaryotes (Black 2003).
In 1977, the first alternative splicing was reported that showed adenoviruses produce two
different mRNA from the same parental gene (Berget et al 1977, Chow et al 1977a,
Chow et al 1977b). More than 70 % of human genes undergo the alternative splicing
(Lander et al 2001, Matlin et al 2005). In addition, the exon-exon junction microarray
revealed that at least 74% of multi-exon genes undergo alternative splicing (Johnson et al
2003). Therefore, alternative splicing is the primary source of the protein diversity in
higher eukaryotes including human.
There are six different modes of alternative splicing (Figure1-8). The constitutive splicing
pattern is the most common splicing type which contains all exons and removes all
introns. Second common type of alternative splicing is a cassette exon or exon skipping
which include or exclude an exon. The different choice of 5’ or 3’ splice site can be
altered the length of exons in the alternative 5’ and alternative 3’ splice sites. The intron
retention is the splicing failure to remove an intron. Finally, mutually exclusive type is
the multiple cassette exons which are spliced by the different exon skipping in several
choices of exons (Black 2003, Srebrow and Kornblihtt 2006). Such a complex patterns of
alternative splicing produces numerous splicing variants including insertion or deletion of
exons, frame shift, and premature termination codon (Sorek et al 2004). The choice of
exons in alternative spicing is regulated by interaction between cis-acting elements and
trans-acting factors.
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Figure 1-8. Different patterns of alternative splicing. Constitutive splicing produces
mRNA including all exons and excluding all intron. Exon skipping or cassette exon
is the common splicing pattern which includes or excludes exon. Alternative 5’ or 3’
splice sites patterns utilizes a different splice site instead of a normal splice site.
Intron retention is a failure of intron that usually produces a frame shift or a
premature stop codon.

Mutually exclusive is a series of exon skipping by the

selection of an exon from many exons (modified from Srebrow and Kornblihtt 2006).
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1.10 Cis-acting elements in the alternative splicing
Regulation of alternative splicing is similar to the transcription regulation and involves a
cis-acting element (enhancer and silencer sequence) and trans-acting factor (repressor and
activator protein factor). Splicing regulatory elements is named by its physical location
such as exonic splicing enhancer (ESE), intronic splicing enhancer (ISE), exonic splicing
silencer (ESS), and intronic splicing silencer (ISS) (Figure 1-9). These elements interact
with trans-acting factors to activate or suppress the neighboring splicing sites (Black
2003, Matlin et al 2005). In case of splicing enhancer, purine rich enhancer and A/C-rich
enhancer (GAR repeat) have been identified (Coulter et al 1997). In terms of ESE and
ISE’s function, splicing enhancer support weak alternative splice sites and assist
spliceosome and trans-acting factors. Compared to splicing enhancer, splicing silencer is
not well understood but ESS and ISS probably recruits splicing repressor protein to
suppress spliceosome assembly (Srebrow and Kornblihtt 2006).

Figure 1-9. Cis-acting elements in the alternative splicing. Exonic splicing enhancer
(ESE) and intronic splicing enhancer (ISE) activates spliceosome assembly,
indicated by red arrows. Exonic splicing silencer (ESS) and intronic splicing silencer
(ISS) suppresses spliceosome, represented by blue lines (modified from Srebrow and
Kornblihtt 2006).
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1.11 Trans-acting factors in the alternative splicing
There are 4 classes of trans-acting factors that regulate the alternative splicing. The
primary factors are U1, U2, U4, U5, and U6 snRNPs which are spliceosomal components,
interacting with 5’ splice site, 3’ splice site, polypyrimidine tract, and a branch point
(Figure 1-7).
The second group of factors is a serine/arginine-rich protein (SR protein) family,
typically binding to the ESE (Figure 1-10). SR proteins are essential pre-mRNA splicing
factors containing highly conserved the RNA-recognition motif (RRM motif) in Nterminal and arginine/serine domain (RS domain) in C-terminal (Graveley 2000). The
RRM motif plays a role in RNA binding and protein-protein interactions with U1snRNP
and U2AF, suggesting that SR protein regulates splice site selection (Boukis et al 2004,
Wu and Maniatis 1993).
The third group is heterogeneous nuclear ribonucleoprotein (hnRNPs). The hnRNPs are
the most abundant proteins in the nucleus. hnRNP have diverse functions including
assisting trafficking of mRNA, associating with other splicing factors, mRNA stability,
and polyadenylation of mRNA (Krecic and Swanson 1999). hnRNP is contains RRM
motif for binding to mRNA and glycine-rich domain for protein-protein interaction
(Gorlach et al 1993, Martinez-Contreras et al 2007). In case of hnRNP A1 act as a
negative regulator which inhibit U1 snRNP in alternative splicing (Figure 1-10) (Eperon
et al 2000).
Final group of trans-acting factor for alternative splicing is the RNA binding motif
(RBM) family and the CUGBP and ETR-like factors (CELF) family of protein, which
contains RNA binding domain to activate or suppress numerous target mRNA (Han and
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Cooper 2005). Other factors including SR protein kinases, phosphatases, and methylases
can be engaged in the trans-acting factors.

Figure 1-10. Trans-acting elements in the alternative splicing. The basic function of
SR proteins binds to the exonic splicing enhancer (ESE) and promotes exon
definition including recruitment of U2AF and U1 by protein-protein interaction
(Left panel). hnRNPs bind to the exonic splicing silencer (ESS), and then inhibit
exon definition by blocking the interaction between U2AF and the 3’ splice site
(Right panel). In addition, hnRNPs directly compete with SR protein to repress the
binding of U1 and U2 to the exon (modified from House and Lynch 2008).
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1.12 alternative splicing in cancer
A number of studies provide the importance of an alternative splicing in human diseases.
Mutation of splicing regulatory elements on an exon or intron affects the splicing event in
cancer (Grosso et al 2008, Venables et al 2009, Wang and Cooper 2007).
For examples, two point mutations in exon 7 (V211 G>A) and intron 13 (A>T) of the
BRCA2 gene splicing sites produced a truncated protein in its C-terminal region
(Pensabene et al 2009). A splice site mutation of c-Met gene exon14 produces the
juxtamembrane domain deletion in gastric cancer cell line Hs746T (Asaoka et al 2010).
Mutations in cis-acting elements, such as ESE and ESS, can also disturb alternative
splicing. For example, a point mutation of the APC tumor suppressor gene in an ESE site
(the exon 14 1918C>G) perturbed the binding sites of SRp55, hnRNP A1 or ASF/SF2
splicing factor. As a result, exon 14 of APC was completely skipped, leading to a frame
shift and a premature termination codon (Goncalves et al 2009).
Furthermore, mutations can generate new splicing regulatory elements. For example, a
point mutation in intron 1 of the KLF6 gene generates a new binding site for the SR
protein SRp40 (Narla et al 2005). KLF6 acts as a tumor suppressor gene and is
somatically inactivated in prostate cancer (Narla et al 2001). The new SRp40 binding site
produces KLF6 splicing variants which antagonize the biological functions of wild type
KLF6.
There are several examples of alternative splicing isoforms affect to human cancer
including p53, fibronectin, fibroblast growth factor (FGF) receptor, vascular endothelial
growth factor (VEGF) receptor, CD44, and murine double minute (MDM) 2 (Hofstetter
et al 2010, Rennel et al 2009, Srebrow and Kornblihtt 2006). Furthermore, some of the
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alternatively spliced isoforms can accumulate in tumors and are sufficient to promote cell
transformation and metastasis formation in cell culture (Klingbeil et al 2009, Singh et al
2004).
Alteration of SR factors and hnRNP proteins frequently occur in tumors and are
accompanied by alterations in the relative abundance of alternative splicing products, a
typical signature of cancer cells (David et al 2010, Ghigna et al 2008). Cancer cell lines
are frequently characterized by a high level of alternative splicing events that are not
conserved between human and mouse and are not found in physiological tissues (Kan et
al 2005).
The alternative splicing of CD44, a trans-membrane glycoprotein involved in cell to cell
and cell to matrix interactions, is a good example of how alternative splicing in cancer
can be modulated by trans-acting factors (Naor et al 2002). The production of different
CD44 isoforms correlates with changes in the abundance of SR proteins (Huang et al
2007). Several CD44 isoforms have been identified diverse inclusions in proximal extracellular domain of CD44 exons (v1-v10). Wild type CD44 has no alternative exons and
predominantly expressed in normal tissues. However, CD44 isoforms, containing variant
exons v5, v6 and v7, are over-expressed in various tumors and have been implicated in
tumor cell invasion and metastasis (Afify et al 2008, Naor et al 2002).
The functional importance of trans-acting factors in cancer cells reported that splicing
factor SF2/ASF acts as a proto-oncogene and several target genes of SF2/ASF are
essential for the oncogenic activity of S6K1, which is a novel oncogenic isoform of the
mTOR substrate (Karni et al 2007). In addition, up- or down-regulation of RNA binding
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proteins in cancer is associated with alternative splicing of oncogenes or tumorsuppressor genes (Grosso et al 2008).

1.13 RBM5 expression in cancer
RNA binding proteins are involved in diverse RNA metabolism including RNA splicing,
transport, translation, and stability. So far, 15 different RNA binding motif (RBM)
proteins have been identified which contains one to four copies RBM or RNA
recognition motif (RRM), serine/arginine-rich domain or arginine/glycine-rich domain
(Sutherland et al 2005). RBM family proteins are involved in alternative splicing,
apoptosis, and cancer. For example, RBM3 is down-regulated in polyglutamine tractinduced apoptosis (Kita et al 2002) and RBM4 is involved in the splice site selection (Lai
et al 2003). RBM7 may play a role in cell and tissue specific RNA processing (Guo et al
2003). In addition, RBM8 is involved in spliced mRNA transport and the process of
nonsense-mediated decay (NMD) of mRNA containing premature stop codon (Kataoka et
al 2000, Maquat and Carmichael 2001). Although biological functions of many RBM
proteins are still unknown, the biological function of RBM5 is relatively well studied.
RBM5, also known as LUCA-15 or H37, is an RNA binding protein and deletion of this
gene is found in human lung cancer (Oh et al 2002). Recently, it was found that RBM5
regulates alternative splicing between exon-8 and -10 of caspase 2, leading to production
of more pro-apoptotic splicing forms (Fushimi et al 2008). Moreover, alternative splicing
of Fas pre-mRNA produces a membrane-bound receptor that promotes apoptosis and a
soluble isoform that prevents apoptosis; Fas splicing is also regulated by RBM5, which is
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a partner of U2AF, an important splicing factor for early splice-site recognition (Bonnal
et al 2008, Kotlajich and Hertel 2008). In contrast, it has been reported that expression of
RBM5 is increased in breast and ovarian cancers, correlated with HER-2/neu protooncogene (Rintala-Maki et al 2007). Thus, the exact biological activity of RBM5 in
tumorigenesis needs to be elucidated, and investigation of the alternative splicing
mechanism of the individual gene is required.
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Figure 1-11. Regulation of RBM5-mediated alternative splicing. U1 snRNP and
U2AF recognize both 5’and 3’ splice sites. Consequently, SR protein stabilizes crossexon interactions, resulting in constitutive alternative splicing (Left).

In the

presence of RBM5, the interaction between SR protein and spliceosomal
components is masked, thus promoting exon skipping by allowing cross-intron
interaction (Right). Figure is modified from Kotlajich and Hertel 2008.
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1.14 Summary
As discussed in chapter 1, alternative splicing may be a major contributor to
tumorigenesis. The objective of this study was to identify the mechanism of KLF4
alternative splicing in colorectal cancer. Based on preliminary data, we hypothesized that
alternative splicing of KLF4 is regulated by RBM5 in colorectal cancer. Detailed
approaches are described in chapter 3. Briefly, we identified novel alternative splicing
variants of KLF4 in several human cancer cell lines. Sequence analysis revealed that the
smallest KLF4 splicing variant is produced by exon skipping. In addition, we developed
the KLF4 minigene system to investigate the exon skipping mechanism of KLF4 and
found that regulation of alternative splicing of KLF4 is mediated by RBM5. Furthermore,
sulindac

sulfide

(SS)

treatment

altered

KLF4

alternative

splicing

by

the

dephosphorylation of RBM5 in colorectal cancer cells, providing a novel mechanism of
sulindac sulfide effect in anti-cancer activity. Overall, our studies offer a novel
mechanism to regulate tumorigenesis by alternative splicing of KLF4.
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CHAPTER 2
Materials and
Experimental Procedures
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2.1 Cell lines
Human colorectal cancer cell lines (HCT-116, SW480, HT-29 and LoVo) and other cell
lines were purchased from American Type Culture Collection (Manassas, VA). SqCC/Y1,
which is head and neck cancer cell line, was obtained from Dr. Dong M. Shin (Emory
University, Atlanta, GA). HCT-116 and HT-29 were maintained in McCOY’s 5A media.
LoVo, A549 (lung cancer cell), PC-3 (prostate cancer cell) was incubated in Ham’s F12
media. SW480, H292 (lung cancer cell), and SqCC/Y1 was grown in RPMI 1640 media.
MCF-7 (breast cancer cell) was incubated in Dulbecco’s Modified Eagle media (DMEM).
T98G (brain cancer cell) was maintained in EMEM media. CMT-93 (mouse coloreactal
cancer cell) was grown in DMEM media. 3T3-L1 (mouse embryonic fibroblast, preadipocyte) was cultured in DMEM with 10 % bovine calf serum.

SCC7 (mouse

squamous cell) was maintained in MEM media. MEF (mouse embryo fibroblast) was
grown in DMEM media. All media, except DMEM for 3T3-L1 cell line, were
supplemented with 10% (v/v) fetal bovine serum (FBS), and 100U/ml penicillin and 100
μg/ml streptomycin at 37 °C with 5% CO2.

2.2 Molecular biology Kits
Human colon tumor and normal adjacent tissue pairs total RNA was purchased from
Ambion (Austin, TX). RNA isolation kit was purchased from Omega Bio-Tek (Norcross,
GA). iScript cDNA synthesis kit was purchased from Bio-Rad (Hercules, CA). pGEM-T
easy cloning vector, Green Taq polymerase, and in vitro translation kit were obtained
from Promega (Madison, WI). Agarose gel extraction kit and miniprep kit were
purchased Zymo Research (Orange, CA). The QuikChange II site-directed mutagenesis
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kit was obtained from Stratagene (La Jolla, CA). pCR 2.1 TA TOPO cloning, pcDNA3.1
V5-tagged TOPO and pcDNA3.1/CT-GFP-tagged TOPO expression vector were
obtained from Invitrogen (Carlsbad, CA). Enhanced Chemiluminescence (ECL) kit for
western blot and Chemiluminescence nucleic acid detection kit for EMSA was obtained
from Pierce (Rockford, IL). Nuclear extract kit for EMSA was purchased from Active
Motif (Carlsbad, CA). Primers, listed in table 3, were purchased from Operon (Pittsburgh,
PA).

2.3 Antibodies
KLF4, RBM5, and β-Actin primary antibodies were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA). Serine/threonine phospho antibody was purchased from
BD biosciences (San Jose, CA). Antibody for V5 was purchased from Invitrogen
(Carlsbad, CA). Secondary antibodies for western blot and tetramethyl rhodamine isothiocyanaste (TRITC) labeled secondary antibody for immunofluorescence were
purchased from Southern Biotech (Birmingham, AL).

2.4 Chemicals
Sulindac sulfide (SS) was purchased from Calbiochem (San Diego, CA). 5-[[6-[(2fluorophenyl)-methoxy]-2-napthalenyl]methyl]-2,4-thiazolidinedione (MCC-555) was
obtained as a gift from Mitsubishi Pharma Corporation (Tokyo, Japan). Rosiglitazone
(RGZ) and Tolfenamic acid (TA) were purchased from Cayman Chemical Co (Ann
Arbor, MI). 3,3’-diindolylmethane (DIM), and (-)-epigallocatchin-3-gallate (EGCG)
were purchased from Sigma (St. Louis, MO). 4’,6-diamidine-2’-phenylindole
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dihydrochloride (DAPI) for nuclear staining was obtained from Roche Applied Science
(Indianapolis, IN). All other chemicals were purchased from Thermo Fisher Scientific
(Pittsburgh, PA).

2.5 Total RNA isolation
Total RNA was isolated using the RNA isolation kit according to the manufacturer’s
instructions. In case of reagent treatment such as MCC-555, rosiglitazone, TA, sulindac
sulfide, DIM, and EGCG, the cells were grown until 60-70% confluent in 6-well plates.
The cells were incubated with serum free media overnight, and then reagents were treated
in serum free media for 4h or 24h. Next, the cells were washed with phosphate buffered
saline (PBS) and harvested with 350μl of cell lysis buffer. After total RNA isolation,
RNA concentration was measure by spectrophotometer at 260/280nm.

2.6 Reverse Transcription PCR (RT-PCR)
Total RNA (1μg) was reverse-transcribed with the iScript cDNA kit according to the
manufacturer’s instructions. Briefly, 1 μg of total RNA was mixed with 5X iScript
reaction mixture including reverse-transcriptase, dNTP, oligo-dT, and random primers in
PCR tubes. The cDNA synthesis reaction was as followed; 25°C for 5min, 42°C for
30min, 85°C for 5min, and 4°C for holding. After cDNA synthesis, 1/20 of cDNA was
used for the template and PCR was performed using 2X Green Taq polymerase with
primers (see Table 3). In order to perform the PCR reaction for KLF4, the PCR condition
was as followed; 94°C for 30 s, 55°C for 30 s, and 72°C for 2 min for 25 cycles for KLF4
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or 20 cycles for GAPDH, which is internal control. After RT-PCR reaction, samples were
loaded into 1.0% agarose gel with 0.5X TAE buffer (Tris-HCl/acetate/EDTA buffer) and
ethidium bromide, which is a DNA intercalating agent, to visualize DNA under UV. The
agarose gel was separated at 100V for 20min and the intensity of PCR bands were
quantified by using Scion Image software (Frederick, MD). Each sample was normalized
to the intensity value of GAPDH.

2.7 KLF4 cDNA constructs
KLF4L, KLF4M, and KLF4S cDNAs were amplified by RT-PCR using human total RNA
from Ambion. Each KLF4 PCR bands were isolated using agarose gel extraction kit. 100
ng of cDNAs were subcloned into pcDNA 2.1 TOPO cloning vector and then
transformed into DH5α competent bacterial cells on Luria-Bertani (LB) plate containing
100μg/ml ampicillin. After overnight incubation at 37°C, several single colonies were
inoculated into LB broth with 100μg/ml ampicillin and incubated in the bacterial shaker
at 37°C for overnight. Plasmid DNA was purified using Miniprep kit from Zymo
Research and cDNA insert was verified by DNA sequencing. KLF4 cDNAs were
digested with EcoR I and Hind III and then subcloned into V5-tagged-pcDNA3.1
expression vector (Invitrogen). DNA sequence was confirmed by sequencing.

2.8 RBM5 cDNA construct
RBM5 cDNAs were were amplified by RT-PCR using human total RNA from Ambion.
Next, the cDNA was subcloned into pGEM-T easy cloning vector. cDNA was verified
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sequencing. RBM5 cDNA was digested with BamH I and Xba I and then, ligated with
pcDNA 3.1 expression vector. Subcloning procedures occurred as stated.

2.9 KLF4 minigene construct
The KLF4 minigene splicing cassette was generated by amplifying a 1.6 kb genomic
DNA fragment from the KLF4 gene (exon-2 to exon-4) with Pfu polymerase using
human genomic DNA (Promega, WI). KLF4 genomic fragment was subcloned into
pcDNA3.1 CT-GFP-TOPO expression vector digested with Kpn I and Xba I sites and
then verified by sequencing.

2.10 Site-directed mutagenesis
Point mutations of KLF4 minigene and RBM5 were produced by the site-directed
mutagenesis kit (Stratagene, Santa Clara, CA). Briefly, the reaction mixture was as
follow; 10 ng of template DNA, 125 ng of forward and reverse primers, dNTP, and Pfu
polymerase. The reaction mixture was incubated under the following conditions; 94°C
for 1 min (initial step), 94°C for 1min, 58°C for 1min, and 68°C for 9 min for 25 cycles
for KLF4 and 68°C for 10 min for 25 cycles for RBM5. Next, 10 U of Dpn I restriction
enzyme was added into the PCR mixture and incubated at 37°C for 1 h. Subsequently,
1/5 sample was used for transformation into XL-1 blue bacterial competent cells. Each
mutagenesis was carefully confirmed by sequencing.
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Table 3. Primer sequence for KLF4L, KLF4S, RBM5, and the KLF4 minigene
construct.

Primer

Oligo sequence

KLF4 EcoR I F

5’-CGAATTCTATGGCTGTCAGCGACGCG-3’

KLF4 Hind III R

5’-CCCAAGCTTTTAAAAATGCCTCTTCATGTGTAAGGC-3’

KLF4S F

5’-ATGGCTGTCAGCGACGCGCTG-3’

KLF4S R

5’-TTAAAAATGCCTCTTCATGTGTAAGGC-3’

mKLF4 F

5’-ATGGCTGTCAGCGACGCTCTG-3’

mKLF4 R

5’-AAAGTGCCTCTTCATGTGTAAGGC-3’

GAPDHF

5'- GGGCTGCTTTTAACTCTGGT-3’

GAPDHR

5’-TGGCAGGTTTTTCTAGACGG-3’

KLF4 mini F

5’-TGGCTGTCAGCGACGCGCTGCTCC-3’

KLF4 mini R

5’-CTGTGTGGGTTCGCAGGTGTGCCTTG-3’

KLF4miniMF

5’- GTCTCTCCCGCCCTGTTCTTGCAGCGCTTGG-3’

KLF4miniMR

5’-CCAAGCGCTGCAAGAACAGGGCGGGAGAGAC-3’

RBM5 BamH I F

5’-CCGGATCCGGGACAATGGGTTCAGACAAAAGAGTG -3’

RBM5 Xba I R

5’-CCTCTAGACTCTCCATCTCAGTGAACCGGGC -3’

RBM5S69AF

5’-GAAAGAAGGAACGCTGACCGATCCGAAG-3’

RBM5S69AR

5’-CTTCGGATCGGTCAGCGTTCCTTCTTTC-3’
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2.11 Transient transfection and luciferase reporter assays
Transient transfection was performed using PolyJet DNA in vitro transfection reagent
from SignaGen (Ijamsville, MD), according to the manufacturer’s instruction. Briefly,
HCT-116 cells were plated in 12-well plates at 105 cells per well and were grown for 16 h.
Plasmid mixture containing PAI-1, cyclin D1, or TOPFlash luciferase constructs, and
pRL–null (Promega, WI) were transfected and the cells were fed fresh medium (McCoy’s
5A medium with 10% FBS) overnight. After cell harvest using 1X luciferase lysis buffer,
luciferase activity was determined and normalized to the pRL-null luciferase activity
using a dual luciferase assay kit (Promega, WI).

2.12 siRNA experiment
RBM5 siRNA was obtained from Santa Cruz Biotechnology (Santa Cruz, CA). siRNA
treatment was performed using TransIT-TKO transfection reagent from Mirus Bio
(Madison, WI). According to manufacture protocol, HCT-116 cells were plated into 6
well plates at 106 per well and incubated for 16h. Next, the reaction mixture, containing
10 μl TKO reagents in 250 μl serum free McCoy 5A media, was incubated for 5 min at
RT and then, 100 nM RBM5 siRNA was added with additional 20 min incubation. The
siRNA mixture was directly added into HCT-116 cells and incubated 48h.

2.13 Establishment of stable cell line
HCT-116 cells were plated in 6-cm plates and transfected with KLF4 minigene or
CONTROL vector (pcDNA3.1/V5-His-TOPO/LacZ) using LipofectAMINE (Invitrogen,
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Carlsbad, CA), according to the manufacturer‘s protocol. After 24 h, the cells were then
transferred to a 10 cm plate with G418 (800μg/ml) (Stratagene). Selection with G418 was
carried out for 3 weeks and then RT-PCR was carried out to check the stable cell lines.

2.14 Western blot analysis
The cells were grown to 60-80% confluence in 6-cm plates followed by 24 h treatment in
the presence of indicated compounds. The cells were then washed once with PBS and
harvested using ice-cold RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1%
SDS) supplemented with protease inhibitors (1 mM PMSF, 5 μg/ml aprotinin and 5
μg/ml Leupeptin) and phosphatase inhibitors (1 mM Na3VO4 and 1 mM NaF). Cell
lysates were collected and kept on ice for 30 minutes followed by protein collection by
quick centrifugation. The protein concentration was determined by BCA protein assay
(Pierce, Rockford, IL) using bovine serum albumin (BSA) as the standard. Equal aliquots
of 30 μg protein were boiled in 2X loading buffer (0.1 M Tris-Cl, pH 6.8, 4% SDS, 0.2%
Bromophenyl blue, 20% glycerol) for 5 min, and then separated by SDS-PAGE (8-14%
gels), followed by transfer to nitrocellulose membranes (Osmonics, Minnetonka MN) for
1 h. The blots were blocked for 1 h with 5% skim milk in TBS/Tween 0.05% (TBS-T),
and probed with a specific primary antiserum in tris buffered saline (TBS) containing
0.05% Tween-20 (TBS-T) and 5% non-fat dry milk at 4°C overnight. After washing with
TBS-T, the blots were treated with horseradish peroxidase-conjugated secondary
antibody for 1 h and washed several times. Proteins were detected by the enhanced
chemiluminescence system (Pierce).
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2.15 Nickel pull-down analysis
HCT-116 cells were transiently transfected with either RBM5 expression vector
(pcDNA3.1/V5-His-TOPO/RBM5) or control vector (pcDNA3.1/V5-His-TOPO/LacZ)
using Lipofectamin2000 (Invitrogen) according to the manufacturer‘s protocol. The
RBM5 proteins containing six histidine residues at their C-termini were purified using
ProBond nickel-chelating resin (Invitrogen), under native condition buffer (50 mM
NaH2PO4/pH 8.0, 500 mM NaCl, 1 mM PMSF, 1 μg/ml aprotinin, 1 μg/ml leupeptin),
and subsequently incubated with 50 μL of ProBond Resin (50% Slurry in 20% ethanol)
for 30 min at 4°C. Beads were then washed three times, boiled for 5 min, and loaded on
SDS/PAGE for Western blot analysis.

2.16 Immunofluorescence
Immunofluorescence was performed as described previously (Lee et al 2008). Briefly, the
cells were washed with PBS, fixed with 4% paraformaldehyde for 30 min, and washed
three times with PBS for 5 min. The cells were incubated with anti-V5 primary antibody
overnight at 4̊C and then with goat anti -mouse TRITC conjugate for 1 h at room
temperature in the dark. The cells were stained with 0.5 mg/ml of DAPI for 10 min to
counterstain the nucleus. The expression of proteins was detected using a Nikon Eclipse
E600 fluorescence microscope. The TIF images were captured using QCapture software
version 2.66.4 with X400 magnification.

2.17 Electrophoretic mobility shift assay (EMSA)
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KLF4L and KLF4S proteins were prepared following the manufacturer’s protocols
(Promega, WI) using the KLF4L and KLF4S pGEM-T easy construct. Synthetic
oligonucleotides corresponding to the KLF4 binding site contained the following
sequence: 5'-ATGCAGGAGAAAGAAGGGCGTAGTATCTACTAG-3' (Shields and
Yang 1998). EMSA was performed using a Light Shift Chemiluminescent EMSA kit
following

the

manufacturer’s

protocols

(Pierce,

IL).

Briefly,

biotin-labeled

oligonucleotide (10 nM) was incubated with purified nuclear extract or in vitro translated
KLF4 (5 μg), 1X binding buffer, 2.5% glycerol, 5 mM MgCl2, 50 ng/μl Poly (dI·dC), and
0.05% NP-40 at room temperature for 20 min. For competition assay, nuclear extracts
were preincubated with the unlabeled oligonucleotide (10X and 100X) for 10 min. DNAprotein complexes were resolved by 5% nondenaturing polyacrylamide gel and
transferred to a nylon membrane, followed by chemiluminescent nucleic acid detection
according to the manufacturer’s protocols.

2.18 Human normal and adjacent tumor tissues
These samples were generously provided by Dr. Joo-Heon Yoon (Yonsei University,
Korea). This study was approved by the Institutional Review Board of Yonsei University
Health System, and all specimens were supported by the Colon Cancer Specimen Bank
from the National Research Resource Bank Program of the Korea Science and
Engineering Foundation in the Ministry of Science and Technology. For comparison,
three histologically normal colons and three adjacent to colorectal adenocarcinomas were
selected from the colon cancer patients who were never treated with any therapeutic
purpose.
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2.19 Statistical analysis
Statistical analysis was performed using the unpaired Student t test. *p<0.05, **p<0.01,
***p<0.001
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CHAPTER 3
Results:
Alternative splicing of KLF4
in colorectal cancer
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3.1 KLF4 splicing variants in human and mouse cancer cells
To investigate the expression of KLF4 mRNA in human and mouse cell lines, we
performed RT-PCR with specific primers covering the coding region of KLF4 mRNA.
The results revealed that at least three KLF4 splicing variants were produced in human
colorectal and non-colorectal cancer cell lines (Figure 3-1A). Hereafter, we designate the
KLF4 splicing variants as large KLF4 (KLF4L), medium KLF4 (KLF4M), and small
KLF4 (KLF4S). The highest amount of KLF4L mRNA expression was observed in LoVo
cells, and the lowest amount of KLF4L was in A549 and PC-3 cells. However, all the
cancer cell lines showed a similar amount of KLF4S mRNA expression. We also tested
KLF4 splicing variants in mouse cell lines by RT-PCR (Figure 3-1B). RT-PCR analysis
revealed that the mouse KLF4 gene generates two splicing variants: mKLF4L and
mKLF4S, indicating that alternative splicing of KLF4 is not only seen in humans but also
in mice.
Since KLF4 protein expression was significantly decreased in gastric and colorectal
cancer (Dang et al 2000a, Wei et al 2005, Zhao et al 2004), we determined whether KLF4
splicing is different in normal and adjacent tumor tissues. Therefore, we attempted to
investigate KLF4L and KLF4S mRNA expression patterns by RT-PCR in human colon
normal and tumor tissue. KLF4S transcripts were significantly detected in both normal
and tumor samples, but the KLF4L transcript level was significantly reduced in tumors
(Figure 3-2).
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Figure 3-1. KLF4 splicing variants in different cell lines. (A) Three major human
KLF4 splicing variants, KLFL, KLFM, and KLFS, were detected by RT-PCR. RTPCR analysis was performed with total RNA extracts from human cancer cell lines.
Colorectal cancer cells are HCT-116, SW480, HT-29, and LoVo. Non-colorectal
cancer cells are H292 (lung), A549 (lung), MCF7 (breast), SqCC/Y1 (head and neck),
PC3 (prostate), and T98G (brain). (B) RT-PCR analysis of KLF4 splicing variants
in mouse cell lines. CMT-93 is a mouse rectal cancer cell. Mouse non-colorectal
cancer cells are 3T3-L1 (fibroblast), SCC7 (squamous cell carcinoma), and mouse
embryonic fibroblast (MEF). Equal loading was confirmed by determining Gapdh
transcript.
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Figure 3-2. KLF4L, KLF4M, and KLF4S in human normal colon and tumor tissue
samples. Human normal tissue (N1) and adjacent human tumor tissue RNAs (T1)
were purchased from Ambion. N2-4 and T2-4 total RNAs were isolated from three
colorectal cancer patients. KLF4 transcripts were analyzed by RT-PCR, and PCR
products were confirmed by sequencing. Quantitative analysis from the RT-PCR is
shown in the graph (Right). Error bars indicate standard deviation. The formula for
the splicing ratio used in this study is as follows. Splicing ratio =
[KLF4S/(KLF4L+KLF4S)]×100
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3.2 KLF4S was produced by exon skipping
To obtain further information of KLF4 splicing variants in humans and mice, we cloned
individual RT-PCR products and verified them by sequencing. Sequence analysis
revealed that the human KLF4S transcript encodes a 154 amino acid protein by exon
skipping (Figure 3-3). The skipped KLF4 exon-3 is the biggest exon, containing a
transcription activation domain and an inhibitory domain (Wei et al 2006). Interestingly,
human KLF4S contains the nuclear localization signal (NLS) and three C2-H2 zinc finger
domains (Figure 3-4). In case of mouse KLF4, mKLF4S was produced by combination of
5’ splice site and 3’ splice site alternative splicing patterns. Also, mKLF4S is missing a
signal peptide and one zinc finger domain (Figure 3-5). It is possible that mKLF4S could
not translocate to the nucleus compared to human KLF4S (Figure 3-6).
Another KLF4 splicing variant KLF4M is produced by the alternative 3’ splice site mode.
However, KLF4M contains a premature termination codon that probably leads to
nonsense-mediated decay (NMD) (Brogna and Wen 2009).
Sequence analysis suggests that human KLF4S might be able to translocate to the nucleus
and bind to KLF4 target gene as an antagonist. Genomic DNA sequence analysis of the
5’ and 3’ splice site regions between human and mouse KLF4 revealed that the second
intron 3’ splice site may be important to exon skipping as a consequence of different
KLF4S splicing patterns between two species (Figure 3-3).
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Figure 3-3. KLF4S is produced by exon skipping. Schematic representation of
human and mouse KLF4 splicing variants. Human KLF4L and KLF4S encode 513
and 154 amino acids, respectively, by exon skipping. KLF4M contains a premature
stop codon and could be degraded by the NMD pathway. Mouse KLF4S (mKLF4S)
are produced by a combination of the 5’ and 3’ alternative splicing sites. The open
box indicates the 5’ and 3’ untranslated region (UTR). The blue box represents the
3rd exon, skipped to generate KLF4S.
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Figure 3-4. Amino acid sequence alignment of human KLF4L and KLF4S. Sequence
alignment was done by using Clustral W2 (http://www.ebi.ac.uk/Tools/clustalw2).
The number indicates amino acid length of KLF4. Nuclear localization signal (NLS)
is indicated by the blue box, and the C2H2 zinc finger domains are indicated by red
boxes.
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Figure 3-5. Amino acid sequence alignment of mouse KLF4L and KLF4S. Sequence
alignment was done by using Clustral W2 (http://www.ebi.ac.uk/Tools/clustalw2).
The number indicates amino acid length of KLF4. Nuclear localization signal (NLS)
is indicated by the blue box, and the C2H2 zinc finger domains are indicated by red
boxes.
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Figure 3-6. Amino acid sequence alignment between human KLF4S and mouse
KLF4S.

Sequence

alignment

was

done

by

using

Clustral

W2

(http://www.ebi.ac.uk/Tools/clustalw2). The number indicates amino acid length of
KLF4. The blue box indicates human KLF4S N-terminal region which encoded by
exon 1 and 2. The red box represents human KLF4S C-terminal region. In mouse
KLF4, red letters and blue letters indicate amino acids joined by combination of 5’
splice site and 3’ splice site alternative splicing.
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3.3 Mutation of the 3’ splice site in the second intron decreased
the KLF4 splicing ratio
To investigate whether the 3’ splicing site of the second intron affects human KLF4 exon
skipping, we established the KLF4 minigene system (Figure 3-8A). The minigene system
is a powerful tool to investigate the cis-acting element or trans-acting factor involving the
alternative splicing event of the multiple-exon gene (Cooper 2005). The human KLF4
genomic fragment, from KLF4 exon-2 to exon-4 containing intron-2 and intron-3, was
subcloned into pcDNA 3.1 CT-GFP vector. Alterative splicing was examined by RTPCR. In addition, three nucleotides on the 3’ splicing site of intron-2 in the human KLF4
gene were mutated to the mouse sequence (Figure 3-7). The wild type and mutated
minigenes were individually transfected into HCT-116 cells and alternative splicing was
determined by RT-PCR using vector-specific primers to discriminate endogenous KLF4
transcripts. The KLF4 minigene system effectively produced the alternative splicing
variants KLF4L and KLF4S, but not KLF4M. Mutation of the 3’splice site in the second
intron significantly suppressed the KLF4 splicing ratio, compared to wild type KLF4 in
the minigene system (Figure 3-8B). This suggests that the 3’ splicing site of the second
intron contains an important cis-acting element for exon skipping of KLF4.
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Figure 3-7. Sequence comparison of the splicing border regions between human and
mouse KLF4 genes. Blue letters indicate the 5’ and 3’ splice site and “-a-” designates
the branch site. Red letters represent different sequences between human and
mouse KLF4.
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Figure 3-8. KLF4 3’splice site suppressed alternative splicing of the KLF4 minigene.
(A) Schematic diagram of the KLF4 minigene, which contained the KLF4 exon 2-4
and intron 2-3. Three nucleotides on the 3’ splice site within the second intron of
human KLF4 were substituted to the mouse KLF4 3’splice site, indicated by red
colors and a red line on the diagram. Arrows indicate primers for determining the
splicing rate of the KLF4 minigene. (B) Mutation of the KLF4 3’splice site
suppressed alternative splicing of the KLF4 minigene. The KLF4 minigene was
transfected into HCT-116 cells and RT-PCR was performed. The graph represents
mean values of KLF4 splicing ratios from three independent experiments. Error
bars, SD.
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3.4 Double 3’ splice sites contribute to the in-frame transcripts
of KLF4
One of the interesting features of KLF4 sequences is that the KLF4 carries a unique
double 3’ splice sites (“agag”) on the intron-3 (Figure 3-9). The exon-3 inclusion on
KLF4L utilizes the first “ag”, whereas the exon inclusion on KLF4S utilizes the second
“ag”. This accurate process prevents the frame shift, resulting in identical C-terminal
sequences in both KLF4L and KLF4S forms. For example, if KLF4L uses the second “ag”
for connecting exon-3 and exon-4, this transcript produces 397 a.a rather than 513 a.a
KLF4 protein by premature stop codon. On the contrary, if KLF4S utilizes the first “ag”
for joining of exon-2 and exon-4, the transcript will be 109 a.a rather than 154 a.a protein.
This is not only seen in human colorectal cancer cell lines, but also seen in KLF4L and
KLF4S splicing variants from human tissue samples (Figure 3-2). To demonstrate the
majority of 3’ splice sites of the KLF4 exon-3 exclusion, RT-PCR products were
carefully investigated by the direct PCR sequencing and minor usage of 3’ splice sites
can be abolished by using this method (Figure 3-9B).
A double 3’ splicing site (agag) in FAS gene (CD95) from autoimmune
lymphoproliferative syndrome (ALPS) patients has been reported (Roesler et al 2005).
However, the double 3’ splice site in KLF4 gene is a natural sequence rather than a point
mutation as seen in FAS gene. Therefore, further studies are necessary to investigate the
regulation mechanism of the KLF4 double 3’ splice sites.
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Figure 3-9. Double 3’ splice sites on intron-3 of KLF4. (A) The double 3’ splice sites
are indicated by red arrows; L is the 3’splice site for KLF4L and S is for KLF4S. (B)
Sequencing data for the exon joining region on the KLF4S. KLF4L contains “ag”,
indicating red letters and red arrow shows the border between exon-3 and exon-4.
Alternative spicing of KLF4S produces without “ag” on border between exon-2 and
exon-4, indicated by red arrow.
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3.5 RBM5 altered the KLF4 splicing ratio
Recent studies showed that RBM5 regulates alternative splicing of FAS and caspase 2
mRNA (Bonnal et al 2008, Fushimi et al 2008). Therefore, we questioned whether KLF4
alternative splicing is also controlled by RBM5. RBM5 expression vector and KLF4
minigene were co-transfected into HCT-116 cells and then alternative splicing was
examined by RT-PCR. Overexpression of RBM5 significantly increased KLF4
alternative splicing ratio, suggesting that RBM5 controls KLF4 splicing (Figure 3-10A).
On the other hand, the down-regulation of RBM5 by siRNA treatment decreased the
KLF4 splicing ratio (Figure 3-10B). Based on these results, RBM5 could be a major
mediator to control KLF4 alternative splicing.

3.6 Sulindac sulfide (SS) restores KLF4L in HCT-116 cells via
RBM5 dephosphorylation
Previously, we reported that various nonsteroidal anti-inflammatory drugs (NSAIDs),
PPARγ ligands, and dietary compounds have anti-tumorigenic effects in colorectal cancer
cells (Sukhthankar et al 2008, Yamaguchi et al 2006). Therefore, we tested whether
treatment with these compounds affects alternative splicing of KLF4. Among those, SS
treatment (10 μM) significantly increased endogenous KLF4L and KLF4M in HCT-116
cells (Figure 3-11A). Using the KLF4 minigene system, we found that SS and MCC-555
suppress the splicing ratio of KLF4 in both HCT-116 and LoVo cells (Figure 3-11B),
respectively; however, RBM5 overexpression increased splicing of the KLF4 minigene in
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both cell lines. These results indicate a pivotal role of RBM5 in KLF4 alternative splicing
in both cells. However, SS and MCC-555 may not be enough to fully increase KLF4L
forms in the presence of RBM5.
Previous report also suggested that RBM5 is a phospho-protein; however, there is no
evidence connecting RBM5 phosphorylation and splicing activation onto its target premRNA (Ekim et al 2003). To test SS effects on the phosphorylation of RBM5, we
performed nickel pull-down followed by western blot using the phospho-serine/threonine
antibody. After SS treatment, total serine/threonine phosphorylation of RBM5 was
decreased in a dose-dependent manner, whereas expression of total RBM5 was not
changed (Figure 3-12A). Additionally, a point mutation of RBM5 at serine 69 (S69A)
showed significant inhibition of KLF4 minigene splicing (Figure 3-12B). Therefore, our
finding suggests that phosphorylation of RBM5 plays a role in KLF4 exon skipping and
SS facilitates dephosphorylation of RBM5, leading to diminished exon skipping. This
could provide a new mechanism of how SS treatment affects anti-tumorigenesis in
colorectal cancer.
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Figure 3-10. Overexpression or knockdown of RBM5 alters the KLF4 splicing ratio.
(A) Overexpression of RBM5 increases alternative splicing of KLF4. KLF4
minigene and V5-tagged RBM5 construct were transfected into HCT-116, and then
the KLF4 splicing ratio was examined by RT-PCR analysis. Overexpression of
RBM5 was confirmed by Western blot analysis using the anti-V5 antibody. (B)
Knockdown of RBM5 by siRNA decreases the KLF4 splicing ratio. RBM5
knockdown was confirmed by Western blot with RBM5 antibody. The bar graphs
on the right represent mean value and the error bar indicates SD from three
independent experiments.
57

Figure 3-11. SS suppresses alternative splicing of KLF4. (A) HCT-116 cells were
starved in serum free-media overnight and then incubated for 4 h with PPAR-γ
ligands, NSAIDs, and dietary compounds; RNA was isolated for RT-PCR analysis.
10 μM SS treatment significantly restored endogenous KLF4L transcripts (V,
vehicle; MCC, 10μM MCC-555; RGZ, 10μM Rosiglitazon; TA, 30μM Tolfenamic
acid; SS, 10μM Sulindac sulfide; DIM, 10μM 3,3'-diindolylmethane; EGCG, 10μM
epigallocatechin gallate). Gapdh is the loading control. (B) RBM5 overexpression
enhanced KLF4 alternative splicing under the KLF4 minigene system. The KLF4
minigene was transiently transfected for 24 h into HCT-116 cells or LoVo cells and
then the cells were treated with vehicle (V), 5 µM MCC-555 (M), and 10 µM SS (S)
for 4 h.
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Figure

3-12.
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splicing.

(A)

Phosphorylation of RBM5 was inhibited by sulindac sulfide treatment. His-tag
RBM5 was pulled down by Ni-agarose bead and western blot was performed with
phospho-serine/threonine antibody. Actin was the loading control. (B) RBM5
mutant (S69A) could not facilitate the KLF4 splicing. The wild type RBM5 and
mutant RBM5 construct were cotranfected with the KLF4 minigene into HCT-116
and the splicing ratio measured by RT-PCR. The bar graphs on the right represent
mean value, and the error bar indicates standard deviation, from three independent
experiments.
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3.7 Biological roles of KLF4S
Significant amounts of KLF4S mRNA and sequence analysis results suggest that KLF4S
could have particular biological activities in the cell. To elucidate biological function of
KLF4S in human colorectal cancer cells, we overexpressed KLF4S into HCT-116 cells.
The V5-tagged KLF4S was detected by Western blot analysis. The extra bands of
overexpression of KLF4L could be degraded forms as previously observed (Shie et al
2000). In addition, endogenous KLF4L expression was examined by using the anti-KLF4
antibody, and all the transfected cells expressed the expected protein as assessed by
Western blot (Figure 3-13).
Based on our sequence analysis, we determined KLF4S could be located in the nucleus
since KLF4S contained a nuclear localized signal (Figure 3-4). To identify the subcellular
localization of KLF4S, we performed immunofluorescence using the anti-V5 antibody in
HCT-116. The lacZ protein, as a control, was predominantly expressed in the cytoplasm,
and KLF4L was highly expressed in the nucleus. However, KLF4S was detected both in
the cytoplasm and nucleus (Figure 3-14A). To verify our immunofluorescence data, we
isolated nuclear and cytoplasm fractions from overexpressed KLF4 cell lysates and then
performed the Western blot with the V5-antibody. We found that lacZ was predominantly
expressed in the cytoplasm, whereas KLF4L was predominantly expressed in the nucleus,
consistent with the immunofluoroscence results; however, KLF4S was expressed in both
cytoplasm and nucleus (Figure 3-14B).
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Figure 3-13. Western blot analysis of human KLF4L and KLF4S transiently
transfected into HCT-116. After 24h Transfection, the cells were harvested with
RIPA buffer. LacZ was used for the control experiment. Overexpressed proteins
were detected by anti-V5 antibody (top). Endogenous KLF4 expression was detected
by anti-KLF4 antibody (middle). Actin is the loading control.
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Figure 3-14. KLF4S has cellular localization and DNA binding activity similar to
KLF4L. (A) Localization of V5-tagged overexpressed KLF4L and KLF4S in HCT116 cells was visualized by fluorescence microscope. The nucleus was stained by
DAPI and TRITC for LacZ, KLF4L, and KLF4S. (B) Localization of KLF4L and
KLF4S was confirmed by Western blot analysis using cytosol fraction (C) and
nucleus fraction (N) from HCT-116. Actin is the loading control.
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Finally, DNA binding activity of KLF4S was investigated by the electrophoretic mobility
shift assay (EMSA) with biotin-labeled oligonucleotides for the KLF4 binding element
(Shields and Yang 1998). Both KLF4L and KLF4S were obtained from the in vitro
translation method and an apparent DNA-protein complex was observed (Figure 3-15). In
addition, the V5-tagged KLF4/DNA complex was recognized on the same membrane by
Western blot. These results suggest that KLF4S is localized in the nucleus and binds to
the KLF4 binding element.
Cyclin D1 is a well known KLF4 target gene (Shie et al 2000). To elucidate KLF4S
transcription activation or repression activity, a -163/+130 cyclin D1 promoter construct
containing a single KLF4 binding site (Castro-Rivera et al 2001) was cotransfected with
either KLF4L, KLF4S, or LacZ into HCT-116. As previously reported, overexpression of
KLF4L suppressed luciferase reporter gene activity (Shie et al 2000). However, KLF4S
did not repress cyclin D1 promoter activity, compared to KLF4L (Figure 3-16). The
Plasminogen activator inhibitor-1 (PAI-1) promoter containing four KLF4 binding sites
was also used to test KLF4s activity (Chen et al 1998). Cotransfection of KLF4L and the 884/+71 PAI-1 promoter construct repressed reporter gene transcription. However, KLFS
slightly inhibited reporter gene transcription compared to the control. These results
suggested that KLF4S is an inactive form of KLF4L.
A recent study showed that KLF4 interacts with the C-terminal of β-catenin, and
inhibition of β-catenin signaling is required in both the N-terminal and C-terminal of the
KLF4 domain (Wang et al 1996). KLF4S contains sufficient domains to bind with βcatenin, but not to inhibit β-catenin activity. Therefore, we tested TOPFlash reporter
construct activity together with KLFL and KLFS (Figure 3-17A). As expected, KLF4L
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inhibited TOPFlash activity; however, KLFS rather enhanced β-catenin signaling in HCT116 cells. To identify whether KLF4S physically interacts with β-catenin, KLF4L and
KLF4S was overexpressed in HCT-116 followed by Ni-agarose pull-down experiment
(Figure 3-17B). Western blot results using β-catenin antibody showed that both KLF4L
and KLF4S strongly bind to β-catenin. Therefore, KLF4S could modulate activity of
KLF4L in Wnt/β-catenin signaling pathway in colorectal cancer.
Together with other results, KLF4S forms may inactivate KLF4L’s tumor suppressor
activity in colorectal tumorigenesis. This is evidence that alternative splicing may provide
an important mechanism for the regulation of tumorigenesis in the human colorectal
tumorigenesis.

3.8 Summary
Based on our results, we propose a model of the KLF4 alternative splicing mechanism
(Figure 3-18), in which KLF4S is produced by exon skipping and antagonize KLF4L
activities, and subsequently enhances tumorigenesis. Phosphorylation of RBM5 also
enhances KLF4 alternative splicing toward KLF4S; however, SS treatments repress KLF4
splicing processes by dephosphorylation of RBM5. Therefore, KLF4 splicing variants
can be used as a potential diagnostic and prognostic marker for human colorectal cancer.
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Figure 3-15. Electrophoretic mobility shift assay (EMSA) analysis of KLFL and
KLF4S. (A) KLF4S is able to bind to the same KLF4L DNA binding site. EMSA
analysis was performed using in vitro translated protein extracts. Western blot
analysis evaluated recombinant KLF4 protein using V5 antibody to detect the DNAprotein complex followed by treatment of the stripping buffer (Thermo Scientific)
on the same membrane. (B) EMSA was performed using nuclear extracts to confirm
the DNA binding activity of KLF4L and KLF4S. The competition of the DNA
binding was obtained using a 10, and 100 time excess of the unlabelled
oligonucleotide.
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Figure 3-16. KLF4S antagonizes KLF4L activity. KLF4S suppresses KLF4L activity
on the cyclin D1 and PAI-1 promoter. The upper diagram indicates cyclin D1 and
PAI-1 luciferase reporter construct containing the KLF4 binding site, indicated by
an arrowhead. KLF4L and KLF4S were co-transfected with cyclin D1 or PAI-1
construct into HCT-116 cells. Luciferase activity was measured as a ratio of firefly
luciferase signal/renilla luciferase signal and is shown as mean ± SD of fold change
over lacZ.
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Figure 3-17. KLF4S interacts with β-catenin. (A) KLF4S is not able to inhibit
TOPFlash reporter activity. The TOPFlash luciferase reporter construct was cotransfected with LacZ, KLF4L, or KLF4S into HCT-116 cells. The represented
results were independently performed three times. Error bars indicates SD. (B)
Interaction between KLF4S and β-catenin was confirmed by Ni-pull down
experiment. Both KLF4L and KLF4S were strongly interacted with β-catenin.
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Figure 3-18. Model of alternative splicing of KLF4 and regulation by RBM5. In case
of normal cells, KLF4L is associated with cell apoptosis, proliferation, and
differentiation. The phosphorylated RBM5 facilitates KLF4 alternative splicing and
generates KLF4S, which inhibit KLF4L functions. In the presence of SS, the RBM5mediated alternative splicing of KLF4 is inhibited and KLF4L mRNA production is
restored in human colorectal cancer cells.
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CHAPTER 4
Discussion
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4.1 Alternative splicing occurs in KLF4 transcription.
Alternative splicing is an important post-transcriptional regulation mechanism to control
normal and cancer cell processes including apoptosis and tumorigenesis. It has been
reported that KLF4 protein level is significantly decreased in adenomas from FAP
patients (Dang et al 2000a, Ton-That et al 1997) and, KLF4 mRNA level is decreased in
adenomas and carcinomas, compared to normal tissue (Shie et al 2000). To our
knowledge, this is the first report that alternative splicing (exon skipping) is observed
during tumorigenesis in the KLF4 gene. Three major variants of KLF4 are found in
cancer cells: KLF4L, KLF4M and KLF4S (Figure 3-1). In addition, KLF4S is generated by
exon skipping and we could detect KLF4S mRNA in most cancer and normal cells. This
obervation was seen in normal colon tissues when RT-PCR was performed using colon
tissues (Figure 3-2). However, the level of KLF4L mRNA was barely detected in both
cancer cell lines and human colon cancer tissue samples. Therefore, alterative splicing is
a major contributor for regulating KLF4L mRNA level in tumorigenesis.

4.2 KLF4S antagonizes with KLF4L biological activity.
To examine the biological function of KLF4S, we overexpressed KLF4S in human
colorectal cancer cells. Interestingly, KLF4S can translocate to the nucleus and bind to the
KLF4 binding site on KLF4 target genes including cyclin D1 and PAI-1, and inhibit βcatenin signaling (Figure 3-16 and 3-17). Particularly, Wnt/β-catenin signaling is crucial
for the maintaining and organizing of the human intestinal epithelium (Pinto et al 2003).
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Recently, KLF4 directly interacts with β-catenin as well as T cell factor 4 (TCF4) to
inhibit β-catenin and p300/CBP complex (Evans et al 2010). In Figure 3-17B, KLF4S
directly interacts with β-catenin, suggesting KLF4S may play a pivotal role in
tumorigenesis. Since KLF4 is a transcription factor and controls many genes involved in
cell proliferation and differentiation, localization of KLF4S in the nuclei implies
inhibition of KLF4 transcriptional activity not only in tumorigenesis, but also in
differentiation. Indeed, KLF4 has been known to be involved in stem cell differentiation
(Guo et al 2009). Further investigation is required to determine the biological
significance of KLF4S in cell differentiation.

4.3 KLF4 splicing profile can be a useful diagnostic tool in
human colorectal cancer.
KLF4L and KLF4S splicing variants were examined in human normal and tumor tissues
by RT-PCR (Figure 3-2). It is interesting that all the normal tissues, but not adjacent
tumor tissues, produced KLF4L and KLF4M. This is consistent with our hypothesis that
the 3’ splicing site in the second intron plays an important role in the KLF4 splicing
mechanism. Based on our sequence analysis, human and mouse KLF4 showed different
3’ splice sites on the second intron, generating different splicing variants (Figure 3-8). It
is possible that a weak 3’ splice recognition site affects alternative splicing of mKLF4,
because the full or partial exon-3 is found in both mKLF4L and mKLF4S. Therefore, we
developed the KLF4 minigene system and mutated the 3’ splice site of intron-2. As
expected, the substitution of the 3’ splice recognition site from human to mouse KLF4
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sequence suppressed the KLF4 splicing ratio (Figure 3-7). In addition, 3’ splice site on
the inton-3 contains the unique double “agag” sequence which showed the exon skipping
dependent manner (Figure 3-9). Based on sequence analysis from human colon normal
and tumor tissue sample, KLF4L utilizes the first “ag” and KLF4S uses the second “ag”,
which produces the same peptide sequences beyond Exon 3. This makes it difficult to
generate a specific antibody for KLF4S peptide. However, if we generated a specific
antibody based on this study, taken together with the identification of mutation at the
splicing site, the KLF4 splicing profiles between normal and tumor samples could be
used for diagnostic and/or prognostic markers for colon cancer in the future.

4.4 RBM5 binding site on the KLF4 mRNA
The identification of cis-acting elements (e.g. exonic splicing enhancer element and
intronic splicing enhancer element) and trans-acting elements within pre-mRNA of KLF4
may give us insights into the relationship between the alternative splicing and
tumorigenesis. To identify RBM5 binding sites on the intron-2 of KLF4, we performed
several

different

experiments

for

RNA-protein

interactions

including

RNA

immunoprecipitation assay, RNA gel shift assay, and biotin labeled-RNA pull-down
assay. Unfortunately, we could not find the specific RBM5 binding site on intron-2. It is
thought that RBM5 may not directly bind to a specific sequence or other cis-acting
elements located in a distant region may be required to provide optimal binding of RBM5
to the RNA sequence. To screen a potential RBM5 binding site on the KLF4 exon-3
which is excluded by the exon skipping, we analyzed sequence using the RESCUE-ESE
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database (http://genes.mit.edu/burgelab/rescue-ese/). There are several potential ESE
sequences to investigate for identification of RBM5 biding site using RNA gel shift assay
and RNA-Chip assay. Since there is no conserved RBM5 binding sequence being
identified, we cannot exclude the possibility that RBM5 may affect splicing without
direct binding to the RNA sequences.

4.5 Therapeutic aspects of KLF4 splicing
Many pharmacological approaches have proposed the use of conventional drug therapy;
oligonucleotide-mediated and RNA-based therapies could be valuable clinical
applications for the alternative splicing-dependent human disease (Garcia-Blanco et al
2004). We screened dietary compounds and the following conventional drugs to examine
whether they affect alternative splicing of KLF4: PPARγ ligands and NSAIDs.
Endogenous KLF4L levels were especially increased by SS, a nonselective
cyclooxygenase inhibitor: SS facilitates the dephophorylation of RBM5, which leads to
inactive RBM5. Although the detailed mechanisms need to be elucidated, this is the first
report suggesting that SS, a known colorectal cancer inhibitor, affects alternative splicing
through the alteration of the spliceosome complex. However, a direct kinase for
phosphorylation of RBM5 is still unknown. There are some reports showed that SR
proteins are phosphorylated to have an effect on RNA-protein interaction and alternative
splicing (Duncan et al 1997, Xiao and Manley 1997). So far, several kinases have been
reported to phosphorylate SR proteins, including SR protein kinase (SRPK) family and
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Cdc2-like kinase (Clk/Sty) family (Cao et al 1997, Jiang et al 2009, Mathew et al 2008,
Ngo et al 2008, Zhong et al 2009). Possibly, SS is potential inhibitor of these kinases.
In contrast, RBM5 phosphorylation could be dephosphorylated by protein phosphatase 1
(PP1). Protein serine/threonine phosphatases or phosphoprotein phosphatases are Mg2+
dependent enzymes. Especially, PP1 is a major phosphatase in this family and very
conserved protein in eukaryotes (Ceulemans and Bollen 2004). PP1 is associated with
regulation of diverse cellular processes including cell signal transduction, stress response,
protein synthesis, cell cycle arrest, and apoptosis (Ceulemans and Bollen 2004, Kwiek et
al 2006). Moreover, PP1 is involved in alternative splicing by dephosphorylation of SR
protein (Massiello and Chalfant 2006). Although there is no evidence that RBM5 is a
target protein of PP1, SS may affect phosphatase activity of PP1 to regulate
dephosphorylation of RBM5.
More than 100 different proteins are involved in spliceosome complex recognition of the
exon-intron boundary, and dozens of serine-arginine factors enhance or repress the
alternative splicing process (Ghigna et al 2008). However, effects of conventional drugs
in the spliceosome complex and splicing process are not known.

4.6 Future directions for alternative splicing in cancer
Importance of alternative spicing in cancer research is emphasized by many studies
(Srebrow and Kornblihtt 2006, Venables 2004, Venables et al 2009, Wang and Cooper
2007). Abnormal alternative splicing is caused by mutations in cis-acting elements
including splicing enhance (ESE and ISE), and silencer (ESS and ISS). Furthermore
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mutations or post-translational modification (phosphorylation, acetylation, etc) on the
trans-acting factor RNA binding protein affect alternative splicing events. Therefore both
cis-acting elements and trans-acting factors can change mRNA splicing profile.
Recent sequencing technology was significantly improved to apply investigation of
splicing profile by whole transcripts sequencing, so called next-generation sequencing or
highthough put sequencing (Marguerat et al 2008, Xiao and Lee 2010). Currently, 454
GS FLX Titanium (Roche) can read 400-600 million bp per single running and SOLiD
system (Applied Biosystem) can generate 15 Giga bp with 50 nt long reads. Using this
system the entire mRNA profile, in other words “transcriptome”, can be monitored.
Therefore, thousands of novel splicing variants by alternative splicing could be
discovered. Moreover, cancer specific alternative splicing profile can be indentified by
using combination of next-generation sequencing technique and systematic data analysis
algorithm.
Another advanced technology for alternative splicing is a cross-linking and
immunoprecipitation (CLIP) combined with high-throughput sequencing (HITS)
technique (Licatalosi and Darnell 2010). CLIP method is usually applied for RNAprotein interaction study. Briefly, RNA-protein complex is covalently cross-linked by
UV-irradiation, then RNA-protein complex is purified by immunoprecipitation. Next,
protein bound regions on RNAs is sequenced using HITS technique. Therefore, the
regulatory sequences including ESE, ESS, ISE, and ISS are identified in the whole
transcriptome–wide by systematic sequence analysis. Those regulatory protein binding
regions will represent the essential “footprint” to understand dynamic events of the
alternative splicing regulation. However, there is limitation that has to be overcome the
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specificity of antibody for the RNA binding protein. Finally, various newly developed
techniques will provide global information to investigate the cancer specific alternative
splicing.
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CHAPTER 5
Conclusion:
Alternative splicing of KLF4 plays a role in
tumorigenesis
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Colorectal cancer is the third most common cancer and leading cause of cancer death in
the United States. Colon cancer progression involves in the accumulation of sequential
events that either activate oncogenes or inhibit the action of tumor suppressor genes.
Particularly, Krüppel-like factor 4 (KLF4) is strongly associated with tumorigenesis and
regulation of proliferation of GI tract epithelium (Wei et al 2006). In this dissertation
research, we found novel KLF4 splicing variants produced by exon skipping in human
cancer cell lines as well as colon tumor tissues (Figure 3-1 and Figure 3-2).
Most human genes including KLF4 produce different mRNAs by alternative splicing
mechanism and many abnormal splicing processes are associated with human diseases,
including cancer. However, the molecular relationship between alternative splicing and
tumorigenesis is not well understood. Therefore, we hypothesized that alternative splicing
of KLF4 is involved in colorectal cancer. To investigate mechanism of the KLF4
alternative splicing, we developed KLF4 minigene system (Figure 3-8). Mutation study
of 3’ splice sites on intron-2 showed that mutation of this site suppresses the KLF4 exon
skipping (Figure 3-8). Moreover, sequence analysis revealed that the unique double 3’
splice site contributes to in-frame alternative splice between KLF4L and KLF4S (Figure
3-9).
To identify trans-acting factor for KLF4 splicing, we performed gain and loss of
functional studies with RBM5; RBM5 alters KLF4 splicing ratio (Figure 3-10). In
addition, several anti-tumorigenic compounds were tested for KLF4 splicing (Figure3-11).
Interestingly, sulindac sulfide restored KLF4L expression and this is mediated by
dephosphorylation of RBM5 (Figure 3-12).
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Furthermore, KLF4S localizes in the cytoplasm and nucleus and antagonizes KLF4L
biological functions including the promoter binding activity to KLF4 target gene and
binding with β-catenin (Figure 3-14, 15, 16, and 17).
Our data suggest that RBM5 plays a critical role in alternative splicing of KLF4 and
KLF4S may contribute to colorectal tumorigenesis by competing with KLF4L. In
conclusion, we propose a model of the KLF4 alternative splicing mechanism (Figure 318). Finally, KLF4S can be used as a potential diagnostic and prognostic marker for
human colorectal cancer.

79

REFERENCES

80

Abdel-Rahman WM, Peltomaki P (2004). Molecular basis and diagnostics of hereditary
colorectal cancers. Ann Med 36: 379-388.
Afify A, McNiel MA, Braggin J, Bailey H, Paulino AF (2008). Expression of CD44s,
CD44v6, and hyaluronan across the spectrum of normal-hyperplasia-carcinoma in breast.
Appl Immunohistochem Mol Morphol 16: 121-127.
Alazzouzi H, Alhopuro P, Salovaara R, Sammalkorpi H, Jarvinen H, Mecklin JP et al
(2005). SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 11: 26062611.
Aoki K, Taketo MM (2007). Adenomatous polyposis coli (APC): a multi-functional
tumor suppressor gene. J Cell Sci 120: 3327-3335.
Asaoka Y, Tada M, Ikenoue T, Seto M, Imai M, Miyabayashi K et al (2010). Gastric
cancer cell line Hs746T harbors a splice site mutation of c-Met causing juxtamembrane
domain deletion. Biochem Biophys Res Commun 394: 1042-1046.
Berget SM, Moore C, Sharp PA (1977). Spliced segments at the 5' terminus of
adenovirus 2 late mRNA. Proc Natl Acad Sci U S A 74: 3171-3175.
Black DL (2003). Mechanisms of alternative pre-messenger RNA splicing. Annu Rev
Biochem 72: 291-336.
Bonnal S, Martinez C, Forch P, Bachi A, Wilm M, Valcarcel J (2008). RBM5/Luca15/H37 regulates Fas alternative splice site pairing after exon definition. Mol Cell 32: 8195.
Boukis LA, Liu N, Furuyama S, Bruzik JP (2004). Ser/Arg-rich protein-mediated
communication between U1 and U2 small nuclear ribonucleoprotein particles. J Biol
Chem 279: 29647-29653.
Brogna S, Wen J (2009). Nonsense-mediated mRNA decay (NMD) mechanisms. Nat
Struct Mol Biol 16: 107-113.
Burt R, Neklason DW (2005). Genetic testing for inherited colon cancer.
Gastroenterology 128: 1696-1716.

81

Cao W, Jamison SF, Garcia-Blanco MA (1997). Both phosphorylation and
dephosphorylation of ASF/SF2 are required for pre-mRNA splicing in vitro. RNA 3:
1456-1467.
Castro-Rivera E, Samudio I, Safe S (2001). Estrogen regulation of cyclin D1 gene
expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol
Chem 276: 30853-30861.
Ceulemans H, Bollen M (2004). Functional diversity of protein phosphatase-1, a cellular
economizer and reset button. Physiol Rev 84: 1-39.
Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS
(2005). Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of
colorectal cancer. JAMA 294: 914-923.
Chan AT, Giovannucci EL (2010). Primary prevention of colorectal cancer.
Gastroenterology 138: 2029-2043 e2010.
Chen YQ, Su M, Walia RR, Hao Q, Covington JW, Vaughan DE (1998). Sp1 sites
mediate activation of the plasminogen activator inhibitor-1 promoter by glucose in
vascular smooth muscle cells. J Biol Chem 273: 8225-8231.
Cheng H, Dufu K, Lee CS, Hsu JL, Dias A, Reed R (2006). Human mRNA export
machinery recruited to the 5' end of mRNA. Cell 127: 1389-1400.
Chow LT, Gelinas RE, Broker TR, Roberts RJ (1977a). An amazing sequence
arrangement at the 5' ends of adenovirus 2 messenger RNA. Cell 12: 1-8.
Chow LT, Roberts JM, Lewis JB, Broker TR (1977b). A map of cytoplasmic RNA
transcripts from lytic adenovirus type 2, determined by electron microscopy of
RNA:DNA hybrids. Cell 11: 819-836.
Cooper TA (2005). Use of minigene systems to dissect alternative splicing elements.
Methods 37: 331-340.
Coulter LR, Landree MA, Cooper TA (1997). Identification of a new class of exonic
splicing enhancers by in vivo selection. Mol Cell Biol 17: 2143-2150.

82

Dang DT, Bachman KE, Mahatan CS, Dang LH, Giardiello FM, Yang VW (2000a).
Decreased expression of the gut-enriched Kruppel-like factor gene in intestinal adenomas
of multiple intestinal neoplasia mice and in colonic adenomas of familial adenomatous
polyposis patients. FEBS Lett 476: 203-207.
Dang DT, Pevsner J, Yang VW (2000b). The biology of the mammalian Kruppel-like
family of transcription factors. Int J Biochem Cell Biol 32: 1103-1121.
David CJ, Chen M, Assanah M, Canoll P, Manley JL (2010). HnRNP proteins controlled
by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463: 364-368.
Derynck R, Zhang YE (2003). Smad-dependent and Smad-independent pathways in
TGF-beta family signalling. Nature 425: 577-584.
Downward J (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev
Cancer 3: 11-22.
Duncan PI, Stojdl DF, Marius RM, Bell JC (1997). In vivo regulation of alternative premRNA splicing by the Clk1 protein kinase. Mol Cell Biol 17: 5996-6001.
Ekim M, Ikinciogullari A, Ulukol B, Bakkaloglu SA, Ozkaya N, Kendirli T et al (2003).
Evaluation of nutritional status and factors related to malnutrition in children on CAPD.
Perit Dial Int 23: 557-562.
Eperon IC, Makarova OV, Mayeda A, Munroe SH, Caceres JF, Hayward DG et al (2000).
Selection of alternative 5' splice sites: role of U1 snRNP and models for the antagonistic
effects of SF2/ASF and hnRNP A1. Mol Cell Biol 20: 8303-8318.
Evans PM, Chen X, Zhang W, Liu C (2010). KLF4 interacts with beta-catenin/TCF4 and
blocks p300/CBP recruitment by beta-catenin. Mol Cell Biol 30: 372-381.
Fearon ER, Vogelstein B (1990). A genetic model for colorectal tumorigenesis. Cell 61:
759-767.
Fearon ER (1995). Molecular genetics of colorectal cancer. Ann N Y Acad Sci 768: 101110.

83

Fedor MJ (2008). Alternative splicing minireview series: combinatorial control facilitates
splicing regulation of gene expression and enhances genome diversity. J Biol Chem 283:
1209-1210.
Foster KW, Frost AR, McKie-Bell P, Lin CY, Engler JA, Grizzle WE et al (2000).
Increase of GKLF messenger RNA and protein expression during progression of breast
cancer. Cancer Res 60: 6488-6495.
Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK et al (2005). Induction of
KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates
squamous epithelial dysplasia. Oncogene 24: 1491-1500.
Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY (2008). Up-regulation of the
proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc
Natl Acad Sci U S A 105: 15708-15713.
Garcia-Blanco MA, Baraniak AP, Lasda EL (2004). Alternative splicing in disease and
therapy. Nat Biotechnol 22: 535-546.
Garrett-Sinha LA, Eberspaecher H, Seldin MF, de Crombrugghe B (1996). A gene for a
novel zinc-finger protein expressed in differentiated epithelial cells and transiently in
certain mesenchymal cells. J Biol Chem 271: 31384-31390.
Ghigna C, Valacca C, Biamonti G (2008). Alternative splicing and tumor progression.
Curr Genomics 9: 556-570.
Goncalves V, Theisen P, Antunes O, Medeira A, Ramos JS, Jordan P et al (2009). A
missense mutation in the APC tumor suppressor gene disrupts an ASF/SF2 splicing
enhancer motif and causes pathogenic skipping of exon 14. Mutat Res 662: 33-36.
Gorlach M, Burd CG, Portman DS, Dreyfuss G (1993). The hnRNP proteins. Mol Biol
Rep 18: 73-78.
Goss KH, Groden J (2000). Biology of the adenomatous polyposis coli tumor suppressor.
J Clin Oncol 18: 1967-1979.
Grady WM (2003). Genetic testing for high-risk colon cancer patients. Gastroenterology
124: 1574-1594.

84

Grady WM (2005). Epigenetic events in the colorectum and in colon cancer. Biochem
Soc Trans 33: 684-688.
Graveley BR (2000). Sorting out the complexity of SR protein functions. RNA 6: 11971211.
Grosso AR, Martins S, Carmo-Fonseca M (2008). The emerging role of splicing factors
in cancer. EMBO Rep 9: 1087-1093.
Guo J, Li Z-c, Feng Y-h (2009). Expression and activation of the reprogramming
transcription factors. Biochemical and Biophysical Research Communications 390: 10811086.
Guo TB, Boros LG, Chan KC, Hikim AP, Hudson AP, Swerdloff RS et al (2003).
Spermatogenetic expression of RNA-binding motif protein 7, a protein that interacts with
splicing factors. J Androl 24: 204-214.
Han J, Cooper TA (2005). Identification of CELF splicing activation and repression
domains in vivo. Nucleic Acids Res 33: 2769-2780.
Hare LE, Ditzler CA, Hichens M, Rosegay A, Duggan DE (1977). Analysis of sulindac
and metabolites by combined isotope dilution-radioimmunoassay. J Pharm Sci 66: 414417.
He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT et al (1998).
Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512.
Hofstetter G, Berger A, Fiegl H, Slade N, Zoric A, Holzer B et al (2010). Alternative
splicing of p53 and p73: the novel p53 splice variant p53delta is an independent
prognostic marker in ovarian cancer. Oncogene 29: 1997-2004.
House AE, Lynch KW (2008). Regulation of alternative splicing: more than just the
ABCs. J Biol Chem 283: 1217-1221.
Huang CS, Shen CY, Wang HW, Wu PE, Cheng CW (2007). Increased expression of
SRp40 affecting CD44 splicing is associated with the clinical outcome of lymph node
metastasis in human breast cancer. Clin Chim Acta 384: 69-74.

85

Jiang K, Patel NA, Watson JE, Apostolatos H, Kleiman E, Hanson O et al (2009). Akt2
regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein
phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger
ribonucleic acid. Endocrinology 150: 2087-2097.
Johnson JM, Castle J, Garrett-Engele P, Kan Z, Loerch PM, Armour CD et al (2003).
Genome-wide survey of human alternative pre-mRNA splicing with exon junction
microarrays. Science 302: 2141-2144.
Jurica MS, Moore MJ (2003). Pre-mRNA splicing: awash in a sea of proteins. Mol Cell
12: 5-14.
Kaczynski J, Cook T, Urrutia R (2003). Sp1- and Kruppel-like transcription factors.
Genome Biol 4: 206.
Kan Z, Garrett-Engele PW, Johnson JM, Castle JC (2005). Evolutionarily conserved and
diverged alternative splicing events show different expression and functional profiles.
Nucleic Acids Res 33: 5659-5666.
Karni R, de Stanchina E, Lowe SW, Sinha R, Mu D, Krainer AR (2007). The gene
encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 14: 185193.
Kataoka N, Yong J, Kim VN, Velazquez F, Perkinson RA, Wang F et al (2000). PremRNA splicing imprints mRNA in the nucleus with a novel RNA-binding protein that
persists in the cytoplasm. Mol Cell 6: 673-682.
Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW et al (2002). The
zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells
in the colon. Development 129: 2619-2628.
Katz JP, Perreault N, Goldstein BG, Actman L, McNally SR, Silberg DG et al (2005).
Loss of Klf4 in mice causes altered proliferation and differentiation and precancerous
changes in the adult stomach. Gastroenterology 128: 935-945.
Kita H, Carmichael J, Swartz J, Muro S, Wyttenbach A, Matsubara K et al (2002).
Modulation of polyglutamine-induced cell death by genes identified by expression
profiling. Hum Mol Genet 11: 2279-2287.
86

Klingbeil P, Marhaba R, Jung T, Kirmse R, Ludwig T, Zoller M (2009). CD44 variant
isoforms promote metastasis formation by a tumor cell-matrix cross-talk that supports
adhesion and apoptosis resistance. Mol Cancer Res 7: 168-179.
Kotlajich MV, Hertel KJ (2008). Death by splicing: tumor suppressor RBM5 freezes
splice-site pairing. Mol Cell 32: 162-164.
Krecic AM, Swanson MS (1999). hnRNP complexes: composition, structure, and
function. Curr Opin Cell Biol 11: 363-371.
Kwiek NC, Thacker DF, Datto MB, Megosh HB, Haystead TA (2006). PITK, a PP1
targeting subunit that modulates the phosphorylation of the transcriptional regulator
hnRNP K. Cell Signal 18: 1769-1778.
Lai MC, Kuo HW, Chang WC, Tarn WY (2003). A novel splicing regulator shares a
nuclear import pathway with SR proteins. EMBO J 22: 1359-1369.
Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J et al (2001). Initial
sequencing and analysis of the human genome. Nature 409: 860-921.
Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S et al (2008). ESE-1/EGR1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells.
Mol Cancer Ther 7: 3739-3750.
Licatalosi DD, Darnell RB (2010). RNA processing and its regulation: global insights
into biological networks. Nat Rev Genet 11: 75-87.
Luk GD (1996). Prevention of gastrointestinal cancer--the potential role of NSAIDs in
colorectal cancer. Schweiz Med Wochenschr 126: 801-812.
Lynch HT, Smyrk TC, Watson P, Lanspa SJ, Lynch JF, Lynch PM et al (1993). Genetics,
natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal
cancer: an updated review. Gastroenterology 104: 1535-1549.
Lynch HT (1999). Hereditary nonpolyposis colorectal cancer (HNPCC). Cytogenet Cell
Genet 86: 130-135.

87

Maquat LE, Carmichael GG (2001). Quality control of mRNA function. Cell 104: 173176.
Marguerat S, Wilhelm BT, Bahler J (2008). Next-generation sequencing: applications
beyond genomes. Biochem Soc Trans 36: 1091-1096.
Marnett LJ (1992). Aspirin and the potential role of prostaglandins in colon cancer.
Cancer Res 52: 5575-5589.
Martin A, Schneider S, Schwer B (2002). Prp43 is an essential RNA-dependent ATPase
required for release of lariat-intron from the spliceosome. J Biol Chem 277: 17743-17750.
Martinez-Contreras R, Cloutier P, Shkreta L, Fisette JF, Revil T, Chabot B (2007).
hnRNP proteins and splicing control. Adv Exp Med Biol 623: 123-147.
Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG et al (1994).
Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and
nonulcerogenic. Proc Natl Acad Sci U S A 91: 3228-3232.
Massiello A, Chalfant CE (2006). SRp30a (ASF/SF2) regulates the alternative splicing of
caspase-9 pre-mRNA and is required for ceramide-responsiveness. J Lipid Res 47: 892897.
Mathew R, Hartmuth K, Mohlmann S, Urlaub H, Ficner R, Luhrmann R (2008).
Phosphorylation of human PRP28 by SRPK2 is required for integration of the U4/U6-U5
tri-snRNP into the spliceosome. Nat Struct Mol Biol 15: 435-443.
Matlin AJ, Clark F, Smith CW (2005). Understanding alternative splicing: towards a
cellular code. Nat Rev Mol Cell Biol 6: 386-398.
McGettigan P, Henry D (2006). Cardiovascular risk and inhibition of cyclooxygenase: a
systematic review of the observational studies of selective and nonselective inhibitors of
cyclooxygenase 2. JAMA 296: 1633-1644.
Mulder KM (2000). Role of Ras and Mapks in TGFbeta signaling. Cytokine Growth
Factor Rev 11: 23-35.

88

Naor D, Nedvetzki S, Golan I, Melnik L, Faitelson Y (2002). CD44 in cancer. Crit Rev
Clin Lab Sci 39: 527-579.
Narla G, Heath KE, Reeves HL, Li D, Giono LE, Kimmelman AC et al (2001). KLF6, a
candidate tumor suppressor gene mutated in prostate cancer. Science 294: 2563-2566.
Narla G, Difeo A, Reeves HL, Schaid DJ, Hirshfeld J, Hod E et al (2005). A germline
DNA polymorphism enhances alternative splicing of the KLF6 tumor suppressor gene
and is associated with increased prostate cancer risk. Cancer Res 65: 1213-1222.
Ngo JC, Giang K, Chakrabarti S, Ma CT, Huynh N, Hagopian JC et al (2008). A sliding
docking interaction is essential for sequential and processive phosphorylation of an SR
protein by SRPK1. Mol Cell 29: 563-576.
Oh JJ, West AR, Fishbein MC, Slamon DJ (2002). A candidate tumor suppressor gene,
H37, from the human lung cancer tumor suppressor locus 3p21.3. Cancer Res 62: 32073213.
Pensabene M, Spagnoletti I, Capuano I, Condello C, Pepe S, Contegiacomo A et al
(2009). Two mutations of BRCA2 gene at exon and splicing site in a woman who
underwent oncogenetic counseling. Ann Oncol 20: 874-878.
Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T et al (1997). Sulindac
sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing
prostaglandin levels. Cancer Res 57: 2909-2915.
Pinto D, Gregorieff A, Begthel H, Clevers H (2003). Canonical Wnt signals are essential
for homeostasis of the intestinal epithelium. Genes Dev 17: 1709-1713.
Reed R (1996). Initial splice-site recognition and pairing during pre-mRNA splicing.
Curr Opin Genet Dev 6: 215-220.
Rennel ES, Varey AH, Churchill AJ, Wheatley ER, Stewart L, Mather S et al (2009).
VEGF(121)b, a new member of the VEGF(xxx)b family of VEGF-A splice isoforms,
inhibits neovascularisation and tumour growth in vivo. Br J Cancer 101: 1183-1193.
Rintala-Maki ND, Goard CA, Langdon CE, Wall VE, Traulsen KE, Morin CD et al
(2007). Expression of RBM5-related factors in primary breast tissue. J Cell Biochem 100:
1440-1458.
89

Roesler J, Izquierdo JM, Ryser M, Rosen-Wolff A, Gahr M, Valcarcel J et al (2005).
Haploinsufficiency, rather than the effect of an excessive production of soluble CD95
(CD95{Delta}TM), is the basis for ALPS Ia in a family with duplicated 3' splice site AG
in CD95 intron 5 on one allele. Blood 106: 1652-1659.
Roscigno RF, Garcia-Blanco MA (1995). SR proteins escort the U4/U6.U5 tri-snRNP to
the spliceosome. RNA 1: 692-706.
Rowland BD, Peeper DS (2006). KLF4, p21 and context-dependent opposing forces in
cancer. Nat Rev Cancer 6: 11-23.
Schreibman IR, Baker M, Amos C, McGarrity TJ (2005). The hamartomatous polyposis
syndromes: a clinical and molecular review. Am J Gastroenterol 100: 476-490.
Segre JA, Bauer C, Fuchs E (1999). Klf4 is a transcription factor required for establishing
the barrier function of the skin. Nat Genet 22: 356-360.
Shen TY, Winter CA (1977). Chemical and biological studies on indomethacin, sulindac
and their analogs. Adv Drug Res 12: 90-245.
Shie JL, Chen ZY, Fu M, Pestell RG, Tseng CC (2000). Gut-enriched Kruppel-like factor
represses cyclin D1 promoter activity through Sp1 motif. Nucleic Acids Res 28: 29692976.
Shields JM, Yang VW (1998). Identification of the DNA sequence that interacts with the
gut-enriched Kruppel-like factor. Nucleic Acids Res 26: 796-802.
Sieber OM, Tomlinson IP, Lamlum H (2000). The adenomatous polyposis coli (APC)
tumour suppressor--genetics, function and disease. Mol Med Today 6: 462-469.
Singh A, Karnoub AE, Palmby TR, Lengyel E, Sondek J, Der CJ (2004). Rac1b, a tumor
associated, constitutively active Rac1 splice variant, promotes cellular transformation.
Oncogene 23: 9369-9380.
Sogawa K, Imataka H, Yamasaki Y, Kusume H, Abe H, Fujii-Kuriyama Y (1993). cDNA
cloning and transcriptional properties of a novel GC box-binding protein, BTEB2.
Nucleic Acids Res 21: 1527-1532.

90

Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P et al (2005).
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma
prevention. N Engl J Med 352: 1071-1080.
Sorek R, Shamir R, Ast G (2004). How prevalent is functional alternative splicing in the
human genome? Trends Genet 20: 68-71.
Srebrow A, Kornblihtt AR (2006). The connection between splicing and cancer. J Cell
Sci 119: 2635-2641.
Sukhthankar M, Yamaguchi K, Lee SH, McEntee MF, Eling TE, Hara Y et al (2008). A
green tea component suppresses posttranslational expression of basic fibroblast growth
factor in colorectal cancer. Gastroenterology 134: 1972-1980.
Suske G, Bruford E, Philipsen S (2005). Mammalian SP/KLF transcription factors: bring
in the family. Genomics 85: 551-556.
Sutherland LC, Rintala-Maki ND, White RD, Morin CD (2005). RNA binding motif
(RBM) proteins: a novel family of apoptosis modulators? J Cell Biochem 94: 5-24.
Tarn WY, Steitz JA (1996). A novel spliceosome containing U11, U12, and U5 snRNPs
excises a minor class (AT-AC) intron in vitro. Cell 84: 801-811.
Tetsu O, McCormick F (1999). Beta-catenin regulates expression of cyclin D1 in colon
carcinoma cells. Nature 398: 422-426.
Thun MJ, Namboodiri MM, Heath CW, Jr. (1991). Aspirin use and reduced risk of fatal
colon cancer. N Engl J Med 325: 1593-1596.
Ton-That H, Kaestner KH, Shields JM, Mahatanankoon CS, Yang VW (1997).
Expression of the gut-enriched Kruppel-like factor gene during development and
intestinal tumorigenesis. FEBS Lett 419: 239-243.
Turner J, Crossley M (1999). Mammalian Kruppel-like transcription factors: more than
just a pretty finger. Trends Biochem Sci 24: 236-240.

91

Ulrich CM, Bigler J, Potter JD (2006). Non-steroidal anti-inflammatory drugs for cancer
prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 6: 130-140.
Vane JR (1971). Inhibition of prostaglandin synthesis as a mechanism of action for
aspirin-like drugs. Nat New Biol 231: 232-235.
Venables JP (2004). Aberrant and alternative splicing in cancer. Cancer Res 64: 76477654.
Venables JP, Klinck R, Koh C, Gervais-Bird J, Bramard A, Inkel L et al (2009). Cancerassociated regulation of alternative splicing. Nat Struct Mol Biol 16: 670-676.
Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009). Genetic
prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499.
Wang GS, Cooper TA (2007). Splicing in disease: disruption of the splicing code and the
decoding machinery. Nat Rev Genet 8: 749-761.
Wang J, Yu P, Lin TC, Konigsberg WH, Steitz TA (1996). Crystal structures of an NH2terminal fragment of T4 DNA polymerase and its complexes with single-stranded DNA
and with divalent metal ions. Biochemistry 35: 8110-8119.
Wei D, Gong W, Kanai M, Schlunk C, Wang L, Yao JC et al (2005). Drastic downregulation of Kruppel-like factor 4 expression is critical in human gastric cancer
development and progression. Cancer Res 65: 2746-2754.
Wei D, Kanai M, Huang S, Xie K (2006). Emerging role of KLF4 in human
gastrointestinal cancer. Carcinogenesis 27: 23-31.
Wielenga VJ, Smits R, Korinek V, Smit L, Kielman M, Fodde R et al (1999). Expression
of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. Am J
Pathol 154: 515-523.
Williams CS, Goldman AP, Sheng H, Morrow JD, DuBois RN (1999). Sulindac sulfide,
but not sulindac sulfone, inhibits colorectal cancer growth. Neoplasia 1: 170-176.
Wu JY, Maniatis T (1993). Specific interactions between proteins implicated in splice
site selection and regulated alternative splicing. Cell 75: 1061-1070.
92

Xiao SH, Manley JL (1997). Phosphorylation of the ASF/SF2 RS domain affects both
protein-protein and protein-RNA interactions and is necessary for splicing. Genes Dev
11: 334-344.
Xiao X, Lee JH (2010). Systems analysis of alternative splicing and its regulation. Wiley
Interdiscip Rev Syst Biol Med 2: 550-565.
Yamaguchi K, Lee SH, Eling TE, Baek SJ (2006). A novel peroxisome proliferatoractivated receptor gamma ligand, MCC-555, induces apoptosis via posttranscriptional
regulation of NAG-1 in colorectal cancer cells. Mol Cancer Ther 5: 1352-1361.
Yoon HS, Chen X, Yang VW (2003). Kruppel-like factor 4 mediates p53-dependent
G1/S cell cycle arrest in response to DNA damage. J Biol Chem 278: 2101-2105.
Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH et al (2000).
The gut-enriched Kruppel-like factor (Kruppel-like factor 4) mediates the transactivating
effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem 275: 18391-18398.
Zhang W, Chen X, Kato Y, Evans PM, Yuan S, Yang J et al (2006). Novel cross talk of
Kruppel-like factor 4 and beta-catenin regulates normal intestinal homeostasis and tumor
repression. Mol Cell Biol 26: 2055-2064.
Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW (2004).
Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal
cancer. Oncogene 23: 395-402.
Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD (2009). Regulation of SR protein
phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1
with molecular chaperones. Genes Dev 23: 482-495.

93

VITA
Jae Hoon Bahn was born Nov 11, 1973 in Seoul, South Korea. He received the degree of
Bachelor of Science from Hallym University in 1999. In the middle of undergraduate study, he
served in Korean Army for 29 months. After graduation, he continued his study with Dr. Soo
Young Choi in the graduate school at Hallym University. He received the Master of Science
degree in 2001. He started graduate study at the University of Tennessee, Knoxville in 2003. He
joined Dr. Seung Joon Baek’ Laboratory in 2007. Since undergraduate, he has 38 peer-reviewed
publications including Oncogene, PNAS, and Genetics. He graduated with a Doctor of
Philosophy in Comparative and Experimental Medicine in the December 2010. He is beginning
his postdoctoral training to study mechanisms of alternative splicing at the University of
California, Los Angeles.
Publications
1.

Bahn JH, Lee SH, Yoon JH, and Baek SJ. Alternative splicing of Kruppel-like factor 4 plays
a role in colorectal tumorigenesis. Oncogene 2010 (Under revision)

2.

Whitlock NC, Bahn JH, Lee SH, Eling TE, and Baek SJ. Early Growth Response-1 and
Krupel-like Factor 4 regulate Resveratrol-induced Activating Transcription Factor 3
expression. Cancer prevention research 2010 (In Press)

3.

Flatland B, Fry MM, Baek SJ, Bahn JH, LeBlanc CJ, Dunlap JR, Carroll RC, Kosiba DJ,
Millsaps DJ, Schleis SE. May-hegglin anomaly in a dog. Vet Clinical Patho 2010 (In press)

94

4. Kim CH, Bahn JH, Lee SH, Kim GY, Jun SI, Lee K, and Baek SJ. Induction of cell growth
arrest by atmospheric non-thermal plasma in colorectal cancer cells. J Biotechnol 2010 (In
press)
5. Lee SH, Bahn JH, Whitlock NC, and Baek SJ. Activating transcription factor 2 (ATF2)
controls tolfenamic acid-induced ATF3 expression via MAP kinase pathways. Oncogene
2010, 29; 5182-5192.
6. Kim CH, Kwon S, Bahn JH, Lee K, Jun SI, Rack PD and Baek SJ. Effects of atmospheric
non-thermal plasma on invasion of colorectal cancer cells. Applied Physics Letters 2010,
96; 243701.
7. Bahn JH, Lee G, and Park JH. Comparative analysis of Pdf-mediated circadian behaviors
between Drosophila melanogaster and D. virilis. Genetics 2009, 181; 965-75.
8. Lee SH, Bahn JH, Choi CK, Whitlock NC, English AE, Safe S, and Baek SJ. ESE-1/EGR1 pathway plays a role in tolfenamic acid-induced apoptosis in colorectal cancer cells. Mol
Cancer Ther. 2008, 7; 3739-50.
9. Lee G, Bahn JH, and Park JH. Sex- and clock-controlled expression of the neuropeptide F
gene in Drosophila. Proc Natl Acad Sci U S A. 2006, 103; 12580-12585.

95

